



NON-INTERVENTIONAL (NI) STUDY PROTOCOL

Study information

Title	Prospective, Registry-Based Observational Cohort Study of Ritlecitinib Safety in Pregnancy
Protocol number	B7981095
Protocol version identifier	Version 3.0
Date	01 February 2025
HMA-EMA catalogue of real-world data sources and studies number	EUPAS1000000296
Active substance	Ritlecitinib, ATC Code L04AF08
Medicinal product	LITFULO
Research question and objectives	Research question: Is there an increased risk of adverse maternal and/or infant outcomes in individuals with alopecia areata (AA) exposed to ritlecitinib during pregnancy? Primary objectives: 1. To estimate the prevalence of major congenital malformation (MCM) births (primary outcome) among individuals with AA who are (1) exposed to ritlecitinib during pregnancy (exposed cohort) and (2) unexposed to ritlecitinib during pregnancy (comparator cohort). 2. To estimate the relative risk (RR) of MCM births in the exposed versus comparator cohort. Secondary objectives: 1. To estimate the prevalence of the following secondary outcomes in the 2 cohorts: spontaneous abortion (SAB), pregnancy termination, pregnancy complications (gestational diabetes, pregnancy-induced hypertension, pre-eclampsia, eclampsia), stillbirth, preterm birth, small for gestational age (SGA), minor congenital malformation, infant serious infection, infant hospitalization, infant death, infant postnatal growth deficiency, and infant developmental delay.

	2. To estimate the RR of each of the secondary outcomes in the exposed versus comparator cohort, if sample size permits.
Authors	Monica Bertoia, MPH, PhD Director, Safety Surveillance Research Worldwide Medical & Safety Pfizer Inc. 66 Hudson Boulevard East New York, NY USA 10001 Telephone: (617) 817-6148 E-mail: monica.bertoia@pfizer.com Syd Phillips, MPH Senior Research Scientist PPD, part of Thermo Fisher Scientific 2157 N. Northlake Way, Seattle, WA 98103 Telephone: (206) 375-1750 E-mail: syd.phillips@thermofisher.com

This document contains confidential information belonging to Pfizer. Except as otherwise agreed to in writing, by accepting or reviewing this document, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer must be promptly notified.

1. TABLE OF CONTENTS

1. TABLE OF CONTENTS.....	3
2. LIST OF ABBREVIATIONS.....	7
3. RESPONSIBLE PARTIES.....	9
4. ABSTRACT.....	10
5. AMENDMENTS AND UPDATES.....	12
6. MILESTONES.....	14
7. RATIONALE AND BACKGROUND.....	15
8. RESEARCH QUESTION AND OBJECTIVES	16
9. RESEARCH METHODS	16
9.1. Study design	16
9.2. Setting.....	17
9.2.1. Inclusion criteria	17
9.2.2. Exclusion criteria	17
9.2.3. Ritlecitinib-exposed cohort.....	18
9.2.4. Comparator cohort	18
9.2.5. Study period.....	18
9.3. Variables.....	18
9.3.1. Pregnancy period	18
9.3.2. Alopecia areata	19
9.3.3. Exposures.....	19
9.3.4. Outcomes	20
9.3.5. Covariates	25
9.4. Data sources	26
9.4.1. Enrollment	26
9.4.2. Data reporters.....	26
9.4.3. Data collection schedule	27
9.4.4. Data collection details.....	27
9.5. Study size	28
9.5.1. Assessment of study feasibility	28
9.5.2. Target enrollment.....	29
9.5.3. Sample size for prevalence	29

9.5.4. Sample size for RR	30
9.6. Data management	33
9.6.1. Data collection tools (DCTs)	33
9.6.2. Record retention	33
9.7. Data analysis	34
9.7.1. Analysis population	34
9.7.1.1. Valid versus invalid participants	34
9.7.1.2. Prospectively enrolled versus retrospectively enrolled participants	34
9.7.1.3. Participants exposed to known teratogens or investigational medications	35
9.7.1.4. Participants exposed to other JAK or TEC kinase inhibitors	35
9.7.1.5. Participants lost to follow-up	36
9.7.1.6. Subsequent pregnancies	36
9.7.1.7. Multiple-gestation pregnancies	36
9.7.2. Descriptive characteristics	36
9.7.3. Outcome prevalence	37
9.7.4. Comparative analyses	38
9.7.4.1. Propensity score modeling	38
9.7.5. Subgroup analyses	39
9.7.6. Supplementary analyses	39
9.7.7. Sensitivity analyses	39
9.7.7.1. Definition of prospective enrollment	39
9.7.7.2. Inclusion of fetal losses in MCM denominator	40
9.7.7.3. Restriction of exposed cohort to participants exposed to ritlecitinib only	40
9.7.7.4. Restriction of comparator cohort to treated participants only	40
9.7.7.5. Exclusion of participants exposed to potential teratogens	40
9.7.8. Missing data	40
9.8. Quality control	40
9.8.1. Steering committee	40

9.9. Limitations of the research methods	41
9.10. Other aspects	42
10. PROTECTION OF HUMAN PARTICIPANTS	42
10.1. Study participant information.....	42
10.2. Participant consent	43
10.2.1. Additional safeguards for children in clinical investigations	43
10.2.2. Electronic informed consent process	44
10.2.3. Waiver of documentation of informed consent	44
10.3. Participant withdrawal.....	45
10.4. IRB/Ethics Committee (EC).....	45
10.5. Ethical conduct of the study	45
11. MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE REACTIONS	46
11.1. Reporting period.....	48
11.2. Causality assessment	48
11.3. Definitions of safety events.....	49
11.3.1. Adverse events.....	49
11.3.2. Serious adverse events	50
11.3.3. Scenarios necessitating reporting to Pfizer Safety within 1 business day/ 3 calendar days.....	51
12. PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS.....	54
13. REFERENCES	55
14. LIST OF TABLES	59
15. LIST OF FIGURES	59
16. LIST OF STAND ALONE DOCUMENTS	60
17. ANNEX 1. RECRUITMENT AND RETENTION STRATEGY	61
17.1. Recruitment strategy	61
17.2. Diversity	61
17.3. Direct-to-HCP outreach.....	61
17.4. Digital advertising	62
17.5. Print advertising	62
17.6. Recruitment materials	63
17.7. Retention strategy.....	63

17.8. Assessment of recruitment and retention	63
18. ANNEX 2. AA TREATMENTS	65
19. ANNEX 3. REGISTRY DATA COLLECTION DETAILS	68
19.1. Information collected at enrollment	68
19.2. Information collected at pregnancy follow-up	70
19.2.1. Follow-up at end of second trimester	70
19.2.2. Follow-up at pregnancy outcome	71
19.3. Information collected at pediatric follow-up.....	72
19.4. Targeted follow-up after report if an event of interest	72
19.5. Attempts to obtain follow-up information	73
19.6. Follow-up process for clarification of information	73
20. ANNEX 4. LIST OF KNOWN TERATOGENS	74

2. LIST OF ABBREVIATIONS

Abbreviation	Definition
AA	alopecia areata
ACOG	American College of Obstetrics and Gynecology
AE	adverse event
AEM	adverse event monitoring
ART	assisted reproductive technology
CDC	Centers for Disease Control and Prevention
CFR	Code of Federal Regulations
CI	confidence interval
DCT	data collection tool
EC	Ethics Committee
EDC	electronic data capture
EDD	estimated date of delivery
EDP	exposure to a drug during pregnancy
FDA	Food and Drug Administration
FSFV	first subject first visit
HCP	healthcare provider
HMA-EMA	Heads of Medicines Agencies-European Medicines Agency
INTERGROWTH-21st	International Fetal and Newborn Growth Consortium for the 21st Century
IPTW	inverse probability of treatment weighting
IRB	institutional review board
IV	intravenous
JAK	Janus kinase
LMP	first day of last menstrual period
LSLV	last subject last visit
MACDP	Metropolitan Atlanta Congenital Defects Program
MCM	major congenital malformation
NA	not applicable
NIS	non-interventional study
PAS	post-authorization study
PASS	post-authorization safety study
PI	principal investigator

Abbreviation	Definition
RR	relative risk
SAB	spontaneous abortion
SAP	statistical analysis plan
SGA	small for gestational age
TEC	tyrosine kinase expressed in hepatocellular carcinoma
TERIS	Teratogen Information System
US	United States
VRCC	virtual registry coordinating center
WHO	World Health Organization

3. RESPONSIBLE PARTIES

Principal Investigator(s) of the Protocol

Name, degree(s)	Job Title	Affiliation	Address
Monica Bertoia, MPH, PhD	Director, Safety Surveillance Research, Worldwide Medical & Safety	Pfizer Inc.	66 Hudson Boulevard East, New York, NY 10001 USA
Syd Phillips, MPH	Senior Research Scientist	PPD, part of Thermo Fisher Scientific	2157 N. Northlake Way, Seattle, WA 98103 USA

4. ABSTRACT

Title: Prospective, Registry-based Observational Cohort Study of Ritlecitinib Safety in Pregnancy

Version 3.0, 01 February 2025

Authors: Monica Bertoia, MPH, PhD, Pfizer Inc.; Syd Phillips, MPH, PPD, part of Thermo Fisher Scientific

Rationale and background: Ritlecitinib (LITFULO™) is a Janus kinase (JAK) 3 and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinase inhibitor approved by the United States (US) Food and Drug Administration (FDA) in June 2023 for the treatment of severe AA in adults and adolescents aged 12 years and older. This non-interventional study (NIS) is designated as a post-authorization safety study (PASS) and will fulfill an FDA post-marketing requirement to assess the safety of ritlecitinib in pregnant individuals.

Research question and objectives:

Research question: Is there an increased risk of adverse maternal and/or infant outcomes in individuals with AA exposed to ritlecitinib during pregnancy?

Primary objectives:

1. To estimate the prevalence of MCM births (primary outcome) among individuals with AA who are (1) exposed to ritlecitinib during pregnancy (exposed cohort) and (2) unexposed to ritlecitinib during pregnancy (comparator cohort).
2. To estimate the RR of MCM births in the exposed versus comparator cohort.

Secondary objectives:

1. To estimate the prevalence of the following secondary outcomes in the 2 cohorts: SAB, pregnancy termination, pregnancy complications (gestational diabetes, pregnancy-induced hypertension, pre-eclampsia, eclampsia), stillbirth, preterm birth, SGA, minor congenital malformation, infant serious infection, infant hospitalization, infant death, infant postnatal growth deficiency, and infant developmental delay.
2. To estimate the RR of each of the secondary outcomes in the exposed versus comparator cohort, if sample size permits.

Study design: Prospective, registry-based observational cohort study. This study will be a new, product-based pregnancy registry.

Population: Two cohorts of pregnant individuals with AA in the US. The study cohorts will include individuals exposed to ritlecitinib during pregnancy and individuals unexposed to ritlecitinib during pregnancy who are enrolled in the registry.

Variables: Exposures to ritlecitinib, other AA treatments, and other medications/substances during pregnancy; AA severity and duration, pregnancy information, study outcomes (MCM,

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF01 6.0 Non-Interventional Study Protocol Template For Primary Data Collection Study

SAB, pregnancy termination, pregnancy complications [pre-eclampsia, eclampsia, gestational diabetes, pregnancy-induced hypertension], stillbirth, preterm birth, SGA, minor congenital malformation, infant serious infection, infant hospitalization, infant death, infant postnatal growth deficiency, and infant developmental delay), and covariates (including demographics, risk factors for the study outcomes, comorbidities, concomitant medications, and predictors of treatment with ritlecitinib).

Data sources: Information on all study variables will be collected from enrolled pregnant individuals and the healthcare providers (HCPs) involved in their care or the care of their infants.

Study size: The registry will aim to enroll 728 pregnant individuals, 364 in each cohort. This sample size will be considered sufficient to achieve its primary objective, to compare the prevalence of MCM in the exposed and comparator cohort.

Data analysis: Participant characteristics will be summarized with descriptive statistics for each cohort. The prevalence of each outcome (primary and secondary) will be calculated in the 2 study cohorts by dividing the number of cases of the outcome by the appropriate denominator for that particular outcome, based on clinical knowledge. Comparative analyses will be conducted for MCM and, if sample size permits, for each of the secondary outcomes. Supplementary analyses will be conducted that include pregnant individuals who were excluded from the analysis population (retrospectively enrolled, exposed to teratogens or investigational medications during pregnancy, or exposed to non-ritlecitinib JAK or TEC kinase inhibitors). If sample size permits, subgroup and sensitivity analyses will be performed to examine the extent to which changes in certain methods or assumptions affect the results.

Milestones: Enrollment of individuals in the registry is expected to begin in October 2024, and data collection will continue through June 2034 (unless target enrollment is achieved earlier). Eight annual interim reports will be submitted to the FDA starting in October 2026, and a final study report will be submitted in June 2035. The annual interim reports will include the registry design, methodology, and results to date, including the number of enrolled participants, their characteristics, and their outcomes, by study cohort. The final comprehensive study report will present results from the full statistical analysis, and an interpretive discussion of the results.

5. AMENDMENTS AND UPDATES

Version Identifier	Date	Amendment Type	Protocol Section(s) Changed	Summary of Amendment(s)	Reason
V3.0	01 February 2025	Administrative	3.0	Replaced PI Katheryne Downes with PI Syd Phillips	Administrative update
V3.0	01 February 2025	Substantial	6.0	Revised from a midpoint to annual interim reports	FDA comments 07 October 2024
V3.0	01 February 2025	Substantial	8	Revised the comparative MCM analysis from a secondary objective to a primary objective	FDA comments 07 October 2024
V3.0	01 February 2025	Substantial	8; 9.1; 9.3.4	Added the following secondary outcomes: gestational diabetes, pregnancy-induced hypertension, infant serious infections, infant hospitalization, and infant death	FDA comments 07 October 2024
V3.0	01 February 2025	Substantial	9.2.2	Explained that pregnancies exposed to teratogens or investigational medications and pregnancies exposed to other JAK or TEC kinase inhibitors will be excluded from the analysis population	FDA comments 07 October 2024
V3.0	01 February 2025	Substantial	9.3.3, Table 9, Table 10	Correction that information on AA and AA treatments will be collected at the 3 key time points: enrollment, end of the second trimester, and end of pregnancy (not on a weekly basis)	Correction
V3.0	01 February 2025	Substantial	9.3.3	Exposure definition revised to at least one dose taken at any time during pregnancy or within 5 half-lives prior to conception (applies to ritlecitinib, other AA treatments, and teratogens)	FDA comments 07 October 2024
V3.0	01 February 2025	Substantial	9.3.5	Added maternal obesity and infant nutrition to the list of covariates	FDA comments 07 October 2024
V3.0	01 February 2025	Substantial	9.5	Revised sample size to align with the MCM comparative analysis	FDA comments 07 October 2024
V3.0	01 February 2025	Substantial	9.7.5	Added a subgroup analysis for system organ class of the defect	FDA comments 07 October 2024

Version Identifier	Date	Amendment Type	Protocol Section(s) Changed	Summary of Amendment(s)	Reason
V3.0	01 February 2025	Substantial	9.8.1	Clarified that one steering committee member will serve as the adjudication tie-breaker when there are discrepancies	Clarification
V3.0	01 February 2025	Substantial	9.9	Added discussion of potential outcome and exposure misclassification and loss to follow-up	FDA comments 07 October 2024
V3.0	01 February 2025	Substantial	20, Annex 4	Revised the list of known teratogens	FDA comments 07 October 2024
V3.0	01 February 2025	Substantial	All sections	Revised terminology from “elective termination” to “pregnancy termination”	FDA comments 07 October 2024
V2.0	15 June 2024	Administrative	3.0	Replaced PI Kristin Veley with PI Katheryne Downes	Administrative update
V2.0	15 June 2024	Administrative	6.0	Added date of draft protocol submission to milestones table	Administrative update
V2.0	15 June 2024	Administrative	19.5	Changed method of communication for final HCP contact attempt to obtain follow-up data (removed “via certified mail”)	Change in HCP communication process

6. MILESTONES

Milestone	Planned date	Actual date
Draft protocol	31 December 2023	19 December 2023
Final protocol	30 June 2024	21 June 2024
Registration in the HMA-EMA catalogue of real-world data sources and studies	Prior to the start of data collection	09 October 2024
Study launch/start of data collection (FSFV) <i>After FDA approval of the final protocol and IRB approval</i>	31 October 2024	31 October 2024
Interim report 1	31 October 2026	
Interim report 2	31 October 2027	
Interim report 3	31 October 2028	
Interim report 4	31 October 2029	
Interim report 5	31 October 2030	
Interim report 6	31 October 2031	
Interim report 7	31 October 2032	
Interim report 8	31 October 2033	
End of enrollment ^a	30 September 2032	
End of data collection (LSLV) ^b	30 June 2034	
Final study report <i>Must be submitted within 12 months of the end of data collection</i>	30 June 2035	

FDA = Food and Drug Administration; FSFV = first subject first visit; HMA-EMA = Heads of Medicines Agencies-European Medicines Agency; IRB = institutional review board; LSLV = last subject last visit

a Date the last individual is enrolled in the study.

b Date the last data point is collected for the study (eg, for the 12-month infant assessment).

7. RATIONALE AND BACKGROUND

On 23 June 2023, the US FDA approved ritlecitinib ([LITFULO™ label 2023](#)), a Janus kinase (JAK) 3 and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinase inhibitor, for the treatment of severe AA in adults and adolescents aged 12 years and older. AA is an autoimmune disease characterized by nonscarring hair loss ranging from small patches to complete scalp, face, and/or body hair loss ([Pratt et al. 2017](#)). In the US, AA has a cumulative lifetime prevalence of 2%, a point prevalence of 0.2%, and an incidence of 92 per 100,000 patient years ([Pratt et al. 2017](#), [Benigno et al. 2020](#), [Mostaghimi et al. 2023](#)).

AA has an underlying immuno-inflammatory pathogenesis and is associated with inflammatory diseases including asthma, allergic rhinitis, and atopic dermatitis, and autoimmune diseases including thyroiditis and vitiligo ([Pratt et al. 2017](#)). Like some other autoimmune diseases, AA may be associated with a higher risk of adverse pregnancy outcomes such as spontaneous abortion ([Cho et al. 2021](#)).

There are limited data on the safety of ritlecitinib use in pregnant individuals ([LITFULO™ label 2023](#)). In rat and rabbit studies, fetotoxicity and fetal malformations were observed at exposures between 49 and 55 times the maximum recommended human dose of 50 mg once daily ([LITFULO™ label 2023](#)). Due to limited human data, the FDA requested a pregnancy registry study be conducted, “preferably a disease-based multiproduct pregnancy registry” with a US study protocol aligned with “protocol(s) outside the US to reach the target sample size” ([LITFULO™ letter 2023](#)). As no existing AA-based pregnancy registries were identified, this will be a new, product-based registry that recruits pregnant individuals with AA as well as pregnant individuals taking ritlecitinib. Unlike the US label, ritlecitinib is contraindicated in pregnancy in the European Union, Great Britain, and Canada labels. Therefore, the registry will launch in the US only, as it is unlikely the registry would enroll a significant number of patients from these non-US countries.

This study will address the gap in information on the safety of ritlecitinib when used in pregnancy in terms of risk of maternal and infant outcomes. This NIS is designated as a PASS and is a post-marketing commitment to the FDA.

8. RESEARCH QUESTION AND OBJECTIVES

Research question: Is there an increased risk of adverse maternal and/or infant outcomes in individuals with AA exposed to ritlecitinib during pregnancy?

Primary objectives:

1. To estimate the prevalence of MCM births (primary outcome) among individuals with AA who are (1) exposed to ritlecitinib during pregnancy (exposed cohort) and (2) unexposed to ritlecitinib during pregnancy (comparator cohort).
2. To estimate the RR of MCM births in the exposed versus comparator cohort.

Secondary objectives:

1. To estimate the prevalence of the following secondary outcomes in the 2 cohorts: SAB, pregnancy termination, pregnancy complications (gestational diabetes, pregnancy-induced hypertension, pre-eclampsia, eclampsia), stillbirth, preterm birth, SGA, minor congenital malformation, infant serious infection, infant hospitalization, infant death, infant postnatal growth deficiency, and infant developmental delay.
2. To estimate the RR of each of the secondary outcomes in the exposed versus comparator cohort, if sample size permits.

9. RESEARCH METHODS

9.1. Study design

This registry-based, prospective observational cohort study will enroll and follow pregnant individuals in the US, including individuals with AA exposed to ritlecitinib during pregnancy and individuals with AA unexposed to ritlecitinib during pregnancy. This study will be a new, product-based pregnancy registry. Participation in the registry is voluntary and participants can withdraw their consent to participate at any time. Data will be collected from enrolled pregnant individuals and the HCPs involved in their care or the care of their infants.

The primary study outcome is MCM and the secondary outcomes are SAB, pregnancy termination, pregnancy complications (pre-eclampsia, eclampsia, gestational diabetes, pregnancy-induced hypertension), stillbirth, preterm birth, SGA, minor congenital malformation, infant serious infection, infant hospitalization, infant death, postnatal growth deficiency, and infant developmental delay. The main measures of effect are the prevalence of each outcome in the 2 study cohorts and the RR of each outcome, comparing the cohorts.

This study design aligns with current FDA guidance for designing and implementing pregnancy exposure registries ([FDA 2019](#)). All assessments described in this protocol are performed as part of normal clinical practice or standard practice guidelines for the patient population and HCP specialty in the countries where this NIS is being conducted. The schedule of office visits and treatment regimens will be determined by HCPs. Only data that are typically documented in participants' medical records during the course of medical care will be collected. No additional laboratory tests or HCP assessments will be required for this study.

9.2. Setting

The 2 study cohorts will be derived from eligible individuals enrolled in the pregnancy registry. The virtual registry coordinating center (VRCC) will coordinate enrollment and data collection (details provided in [Section 9.4](#)). Pregnant individuals will be identified in the US during the study period.

9.2.1. Inclusion criteria

Individuals (of any age) must meet all of the following criteria to be eligible for inclusion in the study:

1. Currently or recently pregnant (recently pregnant defined as enrollment within 1 year of pregnancy outcome)
 - Only prospectively enrolled participants (ie, individuals who are currently pregnant at enrollment) will be included in the analysis population; retrospectively enrolled participants (ie, individuals whose pregnancy outcomes have occurred) will be included in supplementary analyses
2. Have a current diagnosis of AA (confirmed by HCP; see Section 9.3.2)
3. Personally signed and dated informed consent document or, upon waiver of written consent by the relevant IRB/independent ethics committee, verbal consent, indicating that the individual (or a legally acceptable representative) has been informed of all pertinent aspects of the study
4. Authorization for their HCP(s) to provide data to the registry
5. Contact information (for participant and HCPs)

9.2.2. Exclusion criteria

There are no exclusion criteria for this study.

Individuals exposed to teratogens and/or other investigational medications at any time in pregnancy will be excluded from the analysis population (Section 9.7.1.3). Given teratogen exposure is a key risk factor for MCM but not necessarily all secondary outcomes, individuals with teratogen and/or investigational medication exposure during pregnancy will be included in supplementary analyses (Section 9.7.6).

Similarly, individuals exposed to non-ritlecitinib JAK or TEC kinase inhibitors will be excluded from the analysis population (Section 9.7.4.1). However, given the advantages of a treated comparator cohort (Section 9.2.4) and that currently, baricitinib and deuruxolitinib (JAK inhibitors) are the only other FDA-approved treatment for severe AA, these individuals will be included in supplementary analyses (Section 9.7.6).

9.2.3. Ritlecitinib-exposed cohort

Eligible individuals will be included in the ritlecitinib-exposed cohort if they are exposed to ritlecitinib during pregnancy. [Section 9.3.3](#) describes the definition of exposed.

Individuals exposed to both ritlecitinib and other AA treatments (eg, topical steroids) will be included in the exposed cohort. A sensitivity analysis is planned that will restrict the exposed cohort to individuals exposed to ritlecitinib only ([Section 9.7.7.3](#)).

9.2.4. Comparator cohort

All remaining eligible individuals who are not exposed to ritlecitinib during pregnancy will be included in the comparator cohort. This cohort will include individuals who are and are not exposed to (non-ritlecitinib) AA treatments.

If sample size permits, the main analysis will restrict this cohort to treated individuals only, otherwise this restriction will be applied in a sensitivity analysis ([Section 9.7.7.4](#)). The minimum sample size would require 364 treated comparators (for the primary objective; see [Section 9.5.2](#) for details). A treated comparator cohort is expected to improve comparability of the 2 cohorts by selecting groups of individuals with similar AA severity, a potential risk factor for some of the study outcomes. Individuals who are not treated may have milder disease.

9.2.5. Study period

The registry will launch following FDA and institutional review board (IRB) approval of the protocol. Enrollment is expected to begin in October 2024 and end in September 2032. Data collection will continue through June 2034 (unless target enrollment is achieved earlier). For each enrolled pregnant individual, participation will begin at enrollment and end at pregnancy outcome or 12 months after pregnancy outcome (if live birth).

9.3. Variables

9.3.1. Pregnancy period

The registry will conform to the American College of Obstetricians and Gynecologists (ACOG) recommendations for determining the “best” estimated date of delivery (EDD); then, EDD will be used to calculate gestational age. Per ACOG, gestational age and the EDD should be determined by the obstetric HCP as soon as data are obtained regarding the last menstrual period (LMP), first accurate ultrasound, or both. ACOG considers ultrasound measurement of the embryo or fetus in the first trimester (up to and including 13^{6/7} gestational weeks) the most accurate method to establish or confirm gestational age and discourages against changing the EDD based on subsequent ultrasounds. Any pregnancy without an ultrasound before 22^{0/7} gestational weeks to confirm or revise the EDD should be considered suboptimally dated. If the pregnancy resulted from assisted reproductive technology (ART), the obstetric HCP should use ART-derived gestational age (eg, based on age of embryo and date of transfer) to determine EDD. ACOG further recommends that the best estimate of EDD by the obstetric HCP, rather than estimates based on LMP alone, be used for research purposes ([ACOG 2017](#)).

Based on ACOG's recommendations, the registry will collect the EDD from the obstetric HCP, and the HCP will report whether the EDD was calculated based on LMP, ultrasound, or ART data. If ultrasound-based, whether the ultrasound was performed at <14^{0/7}, 14^{0/7} to 21^{6/7}, or ≥22^{0/7} gestational weeks will also be recorded. EDD data will be collected on each data collection form throughout pregnancy. If the HCP reports a corrected EDD on subsequent forms that is different from the EDD initially reported, the registry will evaluate whether a correction is appropriate, based on the timing of the correction and the methods used to determine the corrected EDD, and follow-up with the HCP, if needed. Based on EDD, the following information will be calculated:

- First day of LMP, defined as 0^{0/7} gestational weeks, will be calculated as EDD minus 280 days (40 weeks)
- Gestational age will be calculated as the number of weeks elapsed since the first day of LMP
 - Gestational weeks 0^{0/7} to 13^{6/7} will be considered the first trimester
 - Gestational weeks 14^{0/7} to 27^{6/7} will be considered the second trimester
 - Gestational weeks 28^{0/7} to pregnancy outcome will be considered the third trimester
- Date of conception, defined as 2^{0/7} gestational weeks, will be calculated as first day of LMP plus 14 days (2 weeks)

The pregnancy period will start on the date of conception and end on the pregnancy outcome date

If EDD is not reported by the HCP but LMP data are available, the registry will use first day of LMP to calculate EDD, gestational age, and date of conception.

9.3.2. Alopecia areata

Individuals must have a confirmed, current diagnosis of AA to be eligible for inclusion in the registry. Some individuals may have been diagnosed before conception and others during pregnancy. Individuals will report whether they have been diagnosed with AA and HCPs (obstetric or prescriber) will confirm. HCPs and/or participants will provide details regarding AA severity and date of diagnosis.

It is expected that HCPs will diagnose AA according to the standard clinical criteria outlined by the American Academy of Dermatology (Meah et al. 2021). HCPs will be asked to confirm that the individual was diagnosed with AA, not to confirm that all clinical criteria were met.

9.3.3. Exposures

AA therapy details (prescribed dose, route, frequency, and start/end dates) will be collected from HCPs at enrollment, at the end of the second trimester, and at the pregnancy outcome.

Additional AA therapy (prescription and non-prescription) exposure information will be captured from the participants at the same 3 time points. See [Section 9.4.3](#) for more information.

For all drug exposures (AA treatments, comparator treatments, and teratogens), individuals will be considered exposed during pregnancy if ≥ 1 dose is taken during pregnancy or up to 5 times the product's half-life prior to conception. [ANNEX 2](#) provides a full list of AA treatments and their half-lives. For example, ritlecitinib has a half-life of 1.3 to 2.3 hours ([Annex 2](#)), and 5 times 2.3 hours is 11.5 hours. Since 11.5 hours is less than 1 day, pregnancies will be considered exposed to ritlecitinib if a dose is taken at any time during pregnancy (ie, from the date of conception through the pregnancy end date).

This detailed information will allow for an assessment of temporality between medication exposure and outcome timing. It will also allow exposure to be categorized by trimester ([Section 9.3.1](#)) and by the outcome-specific relevant etiologic period (Table 5).

Depending on the timing of ritlecitinib exposure during pregnancy, some ritlecitinib-exposed individuals will not contribute to all outcome analyses, as each outcome is associated with an outcome-specific relevant etiologic period (summarized in Table 5). For example, the relevant etiologic period for the primary outcome MCM is the first trimester, whereas the relevant etiologic period for SGA is the full pregnancy period. Hence, pregnant individuals who are exposed to ritlecitinib after the first trimester will not contribute to the analysis of MCM.

9.3.4. Outcomes

Table 1 presents the definitions of the outcomes of interest. MCM is the primary outcome of interest and all other outcomes are secondary. Infant outcomes will be identified up to 1 year of age. For outcomes not reported by the HCP, additional information on outcome ascertainment is provided in Table 1.

Table 1. Outcome Definitions and Ascertainment

Outcome	Definition	Additional information on ascertainment
Major congenital malformation (MCM)	An abnormality of body structure or function that is present at birth, is of prenatal origin (ie, birth defect), has significant medical, social, or cosmetic consequences for the affected individual, and typically requires medical intervention (CDC 2020)	The registry defines and codes MCMs with criteria specified by the CDC MACDP (CDC 2021). a) Exclusion criteria for analyses: To avoid misattribution of the malformation to the medication, MCMs not associated with medication exposure, such as chromosomal abnormalities, genetic syndromes, prematurity-related conditions in infants born at <36 gestational weeks (eg, patent ductus arteriosus, patent foramen ovale, inguinal hernias, or undescended testes), and positional effects (eg, hip dislocation due to breech position or abnormal skull shape due to crowding by multiple fetuses), will not be considered MCMs in the statistical analyses (Holmes and Westgate 2011). b) Adjudication process: A panel of 2 independent experts in clinical genetics and neonatology, blinded to exposure, will review all MCMs reported to the registry and classify them using the CDC's MACDP system. Additionally, the birth defect evaluators will provide their opinions regarding the timing of the development of observed defects. If additional information is needed to aid in classification, the birth defect evaluators will request additional information using the targeted follow-up process outlined in Annex 3. These assessments will be recorded in the database. If there is a discrepancy, a third expert will independently review and code the case serving as tie-breaker. These reviews will occur soon after the MCM is reported. Additional reviews will occur if new information is received for the case, as well as the possible temporal association between exposure (to ritlecitinib) and the development of observed defects. Additionally, the steering committee will review all MCM cases reported to the registry and reach consensus on the coding of each case. The Sponsor will not be involved in any activities related to case review or adjudication.
Spontaneous abortion (SAB)	An involuntary fetal loss or the expulsion of the products of conception occurring at <20 gestational weeks	Section 9.3.1 provides information on the methods used to calculate gestational age.
Pregnancy termination	A voluntary fetal loss or interruption of pregnancy that occurs for any reason, including but not limited to for the preservation of maternal health or due to fetal abnormalities	None

Table 1. Outcome Definitions and Ascertainment

Outcome	Definition	Additional information on ascertainment
Pre-eclampsia	A disorder of pregnancy associated with new-onset hypertension, which occurs most often after 20 weeks of gestation and frequently near term, and proteinuria. Or, in the absence of proteinuria, it is defined as new-onset hypertension with the new onset of any of the following: • Thrombocytopenia: platelet count less <100,000/mL • Renal insufficiency: serum creatinine concentrations >1.1 mg/dL or a doubling of the serum creatinine concentration in the absence of other renal disease • Impaired liver function: elevated blood concentrations of liver transaminases to twice normal concentration • Pulmonary edema • New-onset headache unresponsive to medication and not accounted for by alternative diagnoses or visual symptoms (ACOG 2020a)	None
Eclampsia	New-onset tonic-clonic, focal, or multifocal seizures in the absence of other causative conditions such as epilepsy, cerebral arterial ischemia and infarction, intracranial hemorrhage, or drug use (ACOG 2020a)	None

Table 1. Outcome Definitions and Ascertainment

Outcome	Definition	Additional information on ascertainment
Gestational diabetes	Any degree of glucose intolerance with onset or first recognition during pregnancy (Quintanilla 2024)	None
Pregnancy-induced hypertension	A disorder of pregnancy defined as a systolic blood pressure 140 mmHg or more or a diastolic blood pressure of 90 mmHg or more, or both, on 2 occasions at least 4 hours apart after 20 weeks gestation, in a woman with a previously normal blood pressure (ACOG 2020a)	None
Stillbirth	Involuntary fetal loss occurring at ≥ 20 gestational weeks or, if gestational age is unknown, a fetus weighing ≥ 350 g (ACOG 2020b)	Section 9.3.1 provides information on the methods used to calculate gestational age.
Preterm birth	A live birth occurring at < 37 gestational weeks	Section 9.3.1 provides information on the methods used to calculate gestational age.
Small for gestational age (SGA)	Birthweight < 10 th percentile for sex and gestational age using standard growth charts for full and preterm live-born infants (Battaglia and Lubchenco 1967)	For the determination of SGA, the registry will utilize the sex-specific international growth reference standards from the International Fetal and Newborn Growth Consortium for the 21st Century (INTERGROWTH-21 st) for those born between 24 ^{0/7} and 42 ^{6/7} gestational weeks (Villar et al, 2014 ; Villar et al, 2016). The INTERGROWTH-21st standards are the latest available global reference standards, representing contemporary information from an international, multiethnic, diverse population, and have been specifically developed for modern research.
Minor congenital malformation	An anomaly or abnormality of body structure that is present at birth, is of prenatal origin (ie, birth defect), poses no significant health problem in the neonatal period, and tends to have limited social or cosmetic consequences for the affected individual (CDC 2020)	The registry defines and codes minor congenital malformations with criteria specified as defined by CDC (CDC 2019). The same process for adjudicating MCMs will be used to adjudicate minor congenital malformations.

Table 1. Outcome Definitions and Ascertainment

Outcome	Definition	Additional information on ascertainment
Infant serious infection	An infection that occurs within an infant's first year of life and is either opportunistic (ie, occurs more often or is more severe in people with weakened immune systems than in people with healthy immune systems) or serious (ie, results in significant disability, incapacity, or death; is life-threatening; requires inpatient or prolonged hospitalization; or is considered medically important) (CIOMS 2021; Winthrop 2015)	None
Infant hospitalization	An inpatient hospital admission occurring in the first year of life (CIOMS 2021)	None
Infant death	Death of a live-born infant within the first year of life	None
Postnatal growth deficiency	Weight, length, or head circumference in <10 th percentile for sex and chronological age using standard growth charts	Postnatal growth deficiency, as part of routine care, will be evaluated at 4 and 12 months of infant age; deficiencies in weight, length, and head circumference will be evaluated separately. For the determination of postnatal growth deficiency, the registry will utilize the sex-specific international growth reference standards from the WHO for children ages 0 to 59 months. The WHO growth standards are recommended for use in the US for infants and children 0 to 2 years of age (CDC 2010).
Infant developmental delay	Failure to achieve the developmental milestones for chronological age, as defined by the CDC (CDC 2023)	Infant developmental delay, as part of routine care, will be evaluated at 4 and 12 months of infant age for each CDC-defined category (social/emotional, language/communication, cognitive, and movement/physical development), separately.

ACOG = American College of Obstetricians and Gynecologists; CDC = Centers for Disease Control and Prevention; INTERGROWTH-21st = International Fetal and Newborn Growth Consortium for the 21st Century; MACDP = Metropolitan Atlanta Congenital Defects Program; MCM = major congenital malformation; SAB = spontaneous abortion; SGA = small for gestational age; US = United States; WHO = World Health Organization

9.3.5. Covariates

The following variables will be collected (or derived from collected data):

- Geographic region
- Calendar year at conception
- Maternal age at conception
- Maternal race (Asian, American Indian or Alaska Native, Black or African American, Native Hawaiian or Other Pacific Islander, White, other)
- Marital status
- Maternal ethnicity (not Hispanic or Latino, Hispanic or Latino)
- Maternal insurance status (commercial insurance, Medicaid insurance, or uninsured)
- Proxies for maternal socioeconomic status, including maternal education, employment status, and income
- Maternal pre-pregnancy body mass index, calculated from pre-pregnancy weight and height
- Gestational age at registry enrollment
- Method of conception
- Number of fetuses
- Fetal/infant sex
- Concurrent maternal medical conditions, including thyroid abnormalities, infectious diseases, asthma, diabetes, obesity, hypertension, seizure disorder, autoimmune/inflammatory diseases, depression and other psychiatric disorders, hepatitis, sexually transmitted diseases, and uterine or cervical abnormalities (eg, congenital uterine abnormalities)
- Concurrent pregnancy-related maternal medical conditions or pregnancy complications, including gestational diabetes, pregnancy-induced hypertension, pre-eclampsia, eclampsia, preterm labor, placental abruption, and incompetent cervix
- Prenatal testing (current pregnancy)
- Number of previous pregnancies
- Previous pregnancy outcomes (SAB, stillbirth, pregnancy termination, live birth)
- Previous pregnancy complications
- Characteristics of previous live births (preterm, SGA)
- Previous fetus/infant with congenital malformations (major and minor)
- Maternal family history of congenital malformations (major and minor)

- Characteristics of AA disease, including severity immediately prior to pregnancy (ie, to establish baseline severity) and duration (ie, time since diagnosis and age at first diagnosis)
- Maternal exposure to other drugs or biological products, including prescription and non-prescription drugs, dietary supplements (including folic acid and prenatal vitamins), and vaccines, during pregnancy and gestational age at exposure
- Maternal exposure to tobacco, alcohol, marijuana, and recreational or illicit drugs during pregnancy and timing of exposure
- Infant nutrition (ie, breastfeeding and supplementary/formula feeding)

9.4. Data sources

This will be a new, product-based pregnancy registry conducted by PPD (part of Thermo Fisher Scientific). PPD has more than 30 years of experience conducting pregnancy registries and similar studies including more than 50 pregnancy and infant follow-up studies that meet FDA and/or European Medicines Agency guidelines for monitoring pregnancy exposures. The ongoing CIBINQO (abrocitinib) and MONITOR (rimegepant) pregnancy registry PASS studies are 2 such examples ([PPD pregnancy safety study factsheet 2023](#)).

9.4.1. Enrollment

A multi-modal approach will be used to deliver registry education and recruitment materials to targeted HCPs and patients. Recruitment will include pregnant individuals with AA, pregnant individuals taking ritlecitinib, and their HCPs (see [Annex 1](#) for details). This approach involves direct-to-HCP outreach as well as online and print advertising directed to HCPs and patients. Recruitment and retention strategy details (eg, website, HCP brochures) are described in [Annex 1](#).

The VRCC will coordinate enrollment and data collection. Pregnant individuals who are interested in participating in the study will answer a set of screening eligibility questions via a web-based application or by calling the VRCC. If eligible, the individual will be asked to provide informed consent, their primary contact information, alternate contact information, contact information for HCPs who are/will be involved in their care or the care of their infant, and medical releases to allow these HCPs to provide data to the registry.

9.4.2. Data reporters

Information on all study variables will be collected from enrolled pregnant individuals and the HCPs involved in their care or the care of their infants. As described in Table 2, it is anticipated that most obstetric data will be collected from the participant's obstetric HCP (eg, obstetrician, family practitioner, general practitioner who provides care during pregnancy) and that most infant data will be collected from the infant's pediatric HCP (eg, pediatrician, family practitioner, general practitioner who provides pediatric care). After enrollment, the registry may also request data from other HCPs involved in the participant's or infant's care (eg, prescriber, specialist) or from additional HCPs who were not identified at enrollment (eg, if a participant does not know who their pediatric HCP will be at the time of enrollment).

or switches HCPs after enrollment) after appropriate medical releases are obtained from the participant.

Reporters will use electronic forms or paper data collection forms that can be submitted via e-mail/fax, or via phone interview. HCP reporters will be instructed to transcribe data from the participant's or infant's medical records into the data collection forms.

9.4.3. Data collection schedule


All participants will be followed through the end of pregnancy and all live-born infants will be followed through 1 year of age (Figure 1). Information will be collected at enrollment, at the end of the second trimester (approximately 26 gestational weeks), and at the end of pregnancy (live birth or fetal loss). Infant data will be collected at 4 and 12 months of age. Most participants are expected to enroll (first assessment) in the first trimester. The second assessment is scheduled for the end of the second trimester because it is after important diagnostic tests like the 20-week anatomy scan.

Data on AA and exposures to AA therapies (prescription and non-prescription) during pregnancy will be collected from HCPs.

9.4.4. Data collection details

Figure 1 and Table 2 provide a summary of the data collection forms and schedule. Additional details are provided in [ANNEX 3](#), including a summary of information collected at each timepoint (eg, at enrollment, at end of second trimester).

Figure 1. Data Collection Schedule



^a Time to product elimination (5 times terminal half-life); ritlecitinib half-life = 2.3 hours; therefore, time to elimination = 12 hours

^b If a participant is exposed to the product during this time period, she will be considered exposed during pregnancy

^c Participants may be retrospectively enrolled into the registry up to one year after pregnancy outcome but will not be included in main analysis

Table 2. Summary of Data Collection Forms

Data collection form	Reporters	Timing of completion	Data collected
<i>Registration Form for Participants</i>	Participant	Enrollment	• Registration information, including eligibility criteria • Maternal demographic characteristics • Maternal pre-pregnancy anthropometrics
<i>Registration Form for HCPs</i>	Obstetric HCP and prescribing HCP, if needed	Enrollment	• Registration information, including eligibility criteria • Maternal obstetrical history • Family history of congenital malformations • AA information • Baseline pregnancy information
<i>Pregnancy Information Form</i>	Obstetric HCP and prescribing HCP, if needed	Enrollment, end of second trimester*, and EDD/pregnancy outcome*	• Ongoing pregnancy information • Maternal exposures during pregnancy
<i>Pregnancy Outcome Form</i>	Obstetric HCP and pediatric HCP, if needed	EDD/pregnancy outcome	• Pregnancy outcome information
<i>Infant Outcomes Form</i>	Pediatric HCP	4 and 12 months after delivery	• Infant outcome information at 2, 4, 6, and 12 months
<i>Targeted Follow-up Form</i>	Obstetric, pediatric, or other HCP	Any time after pregnancy outcome	• Targeted follow-up information

AA = alopecia areata; EDD = estimated date of delivery; HCP = healthcare provider

* Obtain updated information since the previous contact.

9.5. Study size

9.5.1. Assessment of study feasibility

To assess the feasibility of this study, data-based assumptions regarding the prevalence of AA, pregnancy, and ritlecitinib uptake were made to estimate the number of US individuals who will potentially be exposed to ritlecitinib during pregnancy. The prevalence of AA among individuals of childbearing age was assumed to be like that of the general US population (0.2%; [Mostaghimi et al. 2023](#)). The proportion receiving pharmacotherapy was assumed to be 56% ([Senna et al. 2021](#)). It was further assumed that 1% of those receiving pharmacotherapy would be treated with ritlecitinib.

These assumptions were applied to the population of females of childbearing potential in the US (estimated to be 74,960,628 females aged 15 to 49 years; [US Census 2021](#)), which yielded 840 females of childbearing potential who will potentially receive ritlecitinib. After

application of the general fertility rate in the US (56.0 births per 1,000 females aged 15 to 44 years; [Osterman et al. 2022](#)), it was estimated that 47 live births may potentially be exposed to ritlecitinib in utero. Given the 3% MCM rate among live births ([CDC 2008](#)) in the US general population, these 47 ritlecitinib-exposed live births can be expected to result in approximately 1 live birth with MCM.

If the registry were to capture one-fourth of the live births exposed to ritlecitinib in utero, the registry may not capture any live births with MCMs in the US. Given ritlecitinib is contraindicated in pregnancy in the European Union, Great Britain, and Canada, recruitment of non-US exposed pregnant individuals may be challenging and is unlikely to have a substantial impact on study size.

The frequency of ritlecitinib exposure in US pregnant individuals and their willingness to enroll in a pregnancy registry is unknown. The annual interim reports will provide information on ritlecitinib uptake, recruitment, and study feasibility.

9.5.2. Target enrollment

The registry will target enrolling 364 exposed and 364 comparator pregnancies (728 total) based on the minimum sample size required to detect an MCM RR of 3.0 with 80% power (Section 9.5.4). However, it will be extremely challenging to recruit 364 exposed pregnancies (and 728 total pregnancies) into the registry ([Section 9.5.1](#)).

9.5.3. Sample size for prevalence

Sample size calculations were performed with SAS[®] statistical software (version 9.4 or higher, SAS Institute, Cary, NC) and PASS 2021 Power Analysis and Sample Size software (version 21.0.3, CSS, LLC, Kaysville, Utah). For the calculations, general population prevalence estimates were obtained for the outcomes of interest from various sources, including the Metropolitan Atlanta Congenital Defects Program, National Vital Statistics System, and published literature.

Calculations were performed to determine the achievable precision of outcome prevalence estimates for a range of sample sizes. Table 3 presents the sample size by outcome required to detect a range of precisions, from 1% to 5%. Precision is calculated as the half-width of the two-sided 95% confidence interval (CI) using the Wilson (score) method for binomial proportions.

For example, 145 live births in the analysis population of each cohort would be needed to estimate the prevalence of MCM with $\pm 3\%$ precision. To estimate the number of pregnant individuals who would need to be enrolled to result in 145 live births in the analysis population per cohort, several factors were considered, including the expected proportion of live births in the registry, the proportion of enrolled individuals with exposure to ritlecitinib in the first trimester, and the proportion of enrolled individuals expected to be excluded from the analysis population. Reasons for exclusion from the analysis population are provided in [Section 9.7.1](#). It was assumed that 90% of enrolled individuals would be exposed in the first trimester, 90% of enrolled pregnancies would result in a live birth ([Covington et al. 2010](#); [Veley et al. 2020](#)), and 10% of enrolled individuals would be excluded from the analysis

population. Given these assumptions, to attain 145 live births per cohort, 200 pregnant individuals would need to be enrolled in each of the 2 cohorts.

9.5.4. Sample size for RR

Table 4 presents the sample size needed to detect a range of RRs, by outcome. Using MCM as an example, 265 live births in the analysis population of each cohort are needed to detect an RR of 3.0. Given the same assumptions applied above, to attain 265 live births (with first trimester exposure, if in the exposed cohort) in the analysis population per cohort, 364 pregnant individuals would need to be enrolled in each of the 2 cohorts of the study population, and a total of 728 individuals would need to be enrolled in the registry.

Table 3. Precision-based Sample Size Calculations

Outcome ^a	Reference Prevalence	Reference	Denominator (from rate in literature)	Sample Size Needed per Cohort to Estimate Prevalence with Specified Precision								
				1%	1.5%	2%	2.5%	3%	3.5%	4%	4.5%	5%
MCM	3.0%	CDC 2008	Live births	1,143	521	303	201	145	111	89	73	61
SAB	11.8%	Wu et al. 2019	Pregnant individuals	4,000	1,779	1,002	642	446	328	252	199	162
Pregnancy termination	18.6%	Jatlaoui et al. 2019	Live births	5,815	2,584	1,453	930	645	474	363	286	232
Pre-eclampsia	3.8%	Ananth et al. 2013	Pregnant individuals	1,423	642	369	242	173	131	103	84	70
Eclampsia	0.281%	Butwick et al. 2020	Pregnant individuals	249	150	107	82	67	56	48	42	37
Gestational diabetes	6.9%	Martin et al. 2021	Pregnant individuals	2,475	1,104	625	402	282	209	161	129	105
Pregnancy-induced hypertension	3.0%	Butwick et al. 2020	Pregnant individuals	1,143	521	303	201	145	111	89	73	61
Stillbirth	0.596%	MacDorman and Gregory 2015	Live births and stillbirths	333	184	124	93	74	61	52	45	39
Preterm birth	8.47%	Martin et al. 2021	Singleton live births	2,983	1,329	750	482	336	248	191	152	124
SGA	10.0%	By definition	Singleton live births	3,461	1,540	868	557	388	286	219	174	141
Postnatal growth deficiency	10.0%	By definition	Singleton live births	3,461	1,540	868	557	388	286	219	174	141
Infant developmental delay	13%	Rosenberg et al. 2008	Live births	4,346	1,932	1,087	696	484	356	273	216	175
Infant death	0.6%	Ely and Driscoll 2021	Live births	333	184	124	93	74	61	52	45	39

CDC = Centers for Disease Control; MCM = major congenital malformation; reference prevalence = prevalence of outcome in general population for pregnant individuals of any age; SAB = spontaneous abortion; SGA = small for gestational age

Sample size calculations were performed in the PASS software for the outcomes of interest; precision is calculated as the half-width of the two-sided 95% CI using the Wilson (score) method for binomial proportions.

^a Reference rates for infant hospitalization and infant serious infections were not available for the general population in the US.

Table 4. RR-based Sample Size Calculations

Outcome ^a	Prevalence in unexposed	Reference	Denominator (from rate in literature)	Exposed: comparator ratio	Sample size needed per cohort to detect specified RR							
					1.5	2.0	2.5	3.0	3.5	4.0	4.5	5.0
MCM	3.0%	CDC 2008	Live births	1:1	2,627	796	413	265	190	146	117	97
SAB	11.8%	Wu et al. 2019	Pregnant individuals	1:1	596	177	90	57	40	30	24	19
Pregnancy termination	18.6%	Jatlaoui et al. 2019	Live births	1:1	343	100	50	31	21	15	12	9
Pre-eclampsia	3.8%	Ananth et al. 2013	Pregnant individuals	1:1	2,054	622	322	206	148	113	91	75
Eclampsia	0.281%	Butwick et al. 2020	Pregnant individuals	1:1	28,973	8,824	4,600	2,961	2,130	1,640	1,322	1,101
Gestational diabetes	6.9%	Martin et al. 2021	Pregnant individuals	1:1	1,088	327	169	107	76	58	46	38
Pregnancy-induced hypertension	3.0%	Butwick et al. 2020	Pregnant individuals	1:1	2,627	796	413	265	190	146	117	97
Stillbirth	0.596%	MacDorman and Gregory 2015	Live births and stillbirths	1:1	13,610	4,142	2,159	1,389	999	769	619	516
Preterm birth	8.47%	Martin et al. 2021	Singleton live births	1:1	868	260	134	85	60	46	36	30
SGA	10.0%	By definition	Singleton live births	1:1	721	215	110	70	49	37	29	24
Postnatal growth deficiency	10.0%	By definition	Singleton live births	1:1	721	215	110	70	49	37	29	24
Infant developmental delay	13%	Rosenberg et al. 2008	Live births	1:1	532	158	80	50	35	26	21	17
Infant death	0.6%	Ely and Driscoll 2021	Live births	1:1	13,518	4,115	2,144	1,379	992	763	615	512

CDC = Centers for Disease Control and Prevention; MCM = major congenital malformation; RR = relative risk; SAB = spontaneous abortion; SGA = small for gestational age

Calculations used SAS software (version 9.4), Fisher's exact conditional test with Walters normal approximation method, assuming 80% power and 2-sided α of 0.05. a Reference rates for infant hospitalization, and infant serious infections were not available for the general population in the US.

9.6. Data management

Data will be managed with an electronic data capture (EDC) platform that is compliant with 21 Code of Federal Regulations (CFR) Part 11. Variables will be solicited and entered in the EDC directly by participants or indirectly by VRCC staff. Data provided by participants and/or their HCPs over the phone or on paper data collection forms, which can be submitted to the VRCC via mail, e-mail, or fax, will be reviewed for correctness and completeness and entered into the database by VRCC staff.

Data analyses will be performed using the statistical software program SAS (version 9.4 or higher; SAS Institute, Cary, NC).

9.6.1. Data collection tools (DCTs)

As used in this protocol, the term DCT should be understood to refer to either a paper form or an electronic data record or both, depending on the data collection method used in this study.

A completed DCT is required for each included participant. The completed original DCTs are the sole property of Pfizer and should not be made available in any form to third parties, except for authorized representatives of Pfizer or appropriate regulatory authorities, without written permission from Pfizer. PPD shall ensure that the DCTs are securely stored in an electronic portal or secured in a locked room to prevent access by unauthorized third parties.

PPD has ultimate responsibility for the collection and reporting of all data entered on the DCTs as required and ensuring that they are accurate, authentic/original, attributable, complete, consistent, legible, timely (contemporaneous), enduring, and available when required. The DCT serves as the source document. Any corrections to entries made in the DCTs must be dated, initialed, and explained (if necessary) and should not obscure the original entry.

9.6.2. Record retention

To enable evaluations and/or inspections/audits from regulatory authorities or Pfizer, PPD agrees to keep all study-related records. The records should be retained by PPD according to local regulations or as specified in the vendor contract, whichever is longer. PPD must ensure that the records continue to be stored securely for so long as they are retained.

If PPD becomes unable for any reason to continue to retain study records for the required period, Pfizer should be prospectively notified. The study records must be transferred to a designee acceptable to Pfizer.

Study records must be kept for a minimum of 15 years after completion or discontinuation of the study, unless PPD and Pfizer have expressly agreed to a different period of retention via a separate written agreement. Record must be retained for longer than 15 years if required by applicable local regulations.

PPD must obtain Pfizer's written permission before disposing of any records, even if retention requirements have been met.

9.7. Data analysis

Detailed methodology for summary and statistical analyses of data collected in this study will be documented in a statistical analysis plan (SAP), which will be dated, filed and maintained by the Sponsor. The SAP may modify the plans outlined in the protocol; any major modifications of primary endpoint definitions or their analyses will be reflected in a protocol amendment.

9.7.1. Analysis population

The analysis population will include participants who:

- Are valid (Section 9.7.1.1)
- Are prospectively enrolled (Section 9.7.1.2)
- Are not exposed to teratogens or investigational medications during pregnancy (Section 9.7.1.3)
- Are not exposed to non-ritlecitinib JAK or TEC kinase inhibitors during pregnancy (Section 9.7.1.4)
- Are not considered lost to follow-up (Section 9.7.1.5)

For the analyses of preterm birth, SGA, and postnatal growth deficiency, multiple-gestation pregnancies will be excluded from the analysis population (Section 9.7.1.7).

9.7.1.1. Valid versus invalid participants

A valid participant will be defined as a pregnant individual with sufficient data, submitted or confirmed by an HCP, for determining and meeting inclusion/exclusion into one of the study cohorts. Participants who lack the minimum data required for determining inclusion or exclusion into one of the study cohorts or who lack confirmation of exposure, pregnancy, or AA diagnosis from an HCP will be considered invalid. Invalid participants will be enumerated in each registry report but will not be included in statistical analyses.

9.7.1.2. Prospectively enrolled versus retrospectively enrolled participants

The registry will encourage prospective registration; however, retrospective enrollment in the registry will be permitted as well. A prospectively enrolled participant is defined as a pregnant individual who enrolls prior to the pregnancy outcome. A retrospectively enrolled participant is defined as a pregnant individual who enrolls after the pregnancy outcome has occurred.

Retrospectively enrolled participants can introduce bias toward the reporting of more unusual and severe outcomes and are less likely to be representative of the general population than prospectively enrolled participants. They may also recall past drug exposures differently compared with prospectively enrolled patients. Therefore, retrospectively enrolled

participants will be excluded from the analysis population but will be included in supplementary analyses ([Section 9.7.6](#)).

Diagnostic prenatal tests (eg, ultrasound to scan for structural defects at approximately 20 gestational weeks, chorionic villus sampling, and amniocentesis) can determine with high accuracy whether a fetus has a structural or chromosomal abnormality. Therefore, inclusion of individuals who have had diagnostic prenatal testing in the analysis population may introduce bias. To examine this potential bias, a sensitivity analysis that applies a stricter definition of prospective enrollment will be conducted ([Section 9.7.7.1](#)). For this analysis, individuals who enroll prior to diagnostic prenatal testing will be considered prospectively enrolled, and individuals who enroll after diagnostic prenatal testing, regardless of the results, will be considered retrospectively enrolled. The outcomes of individuals who enroll prior to diagnostic prenatal testing will be compared with those of individuals who enrolled after diagnostic prenatal testing.

9.7.1.3. Participants exposed to known teratogens or investigational medications

Participants will be considered exposed to teratogens or investigational medications if at least one dose is taken at any time during pregnancy or up to 5 times the product half-life prior to conception (see [Section 9.3.3](#) for details). A list of known teratogens ([ANNEX 4](#)) has been developed and will be continually updated based on the data available in the Teratogen Information System (TERIS) database of teratogenic agents and publications ([Polifka 2002](#); [Feldkamp 2015](#); [Zomerdijs 2015](#); [TERIS 2021](#)). Investigational medications include drugs that are not yet approved by the FDA.

Participants who are exposed to known teratogens or investigational medications during pregnancy will be excluded from the analysis population but will be included in supplementary analyses given teratogen exposure is a risk factor for some but not all of the secondary outcomes ([Section 9.7.6](#)).

9.7.1.4. Participants exposed to other JAK or TEC kinase inhibitors

Participants exposed to other JAK or TEC kinase inhibitors will be excluded from the analysis population because the comparison ritlecitinib-exposed to comparator patients may be confounded if both groups include participants exposed to medications of the same class. This would make the interpretation of study results and the detection of potential safety signals more challenging.

Participants will be considered exposed to non-ritlecitinib JAK or TEC kinase inhibitors if a dose is taken at any time during pregnancy (from conception to pregnancy outcome) or prior to pregnancy (at least one dose in time period equivalent to 5 times the product's half-life prior to conception). A list of JAK or TEC kinase inhibitors is included in [Annex 2](#) (AA treatments). This list will be updated over the course of the study to include other new medications approved for this indication.

Participants who are exposed to other JAK or TEC kinase inhibitors will be excluded from the analysis population but will be included in supplementary analyses ([Section 9.7.6](#)), given

baricitinib and deuruxolitinib (JAK inhibitors) are currently the only non-ritlecitinib FDA-approved treatment for severe AA.

9.7.1.5. Participants lost to follow-up

A participant will be considered lost to follow-up if follow-up information is never obtained or is unavailable; pregnant individuals without pregnancy outcome information and live-born infants without follow-up data after birth will be considered lost to follow-up. [ANNEX 3](#) provides more information on the circumstances under which participants will be considered lost to follow-up. Information from these participants (eg, demographic characteristics, abnormal prenatal test results, and reason for loss to follow-up, if available) will be summarized in each registry report, but these participants will be excluded from the analysis population. While infants who are lost to follow-up will not contribute to the analysis of infant outcomes after the point in which they were lost to follow-up, the pregnancy information from their mothers will be included in the analysis of pregnancy outcomes. In addition, the proportion of participants who are lost to follow-up will be compared between the cohorts to assess any potential differential loss to follow-up which could bias the comparative analyses.

9.7.1.6. Subsequent pregnancies

Individuals who have previously enrolled in the registry with a prior pregnancy may enroll in the registry with subsequent pregnancies and contribute multiple pregnancies to the analysis population. Statistical non-independence due to multiple pregnancies from the same individual will be addressed in the analysis.

9.7.1.7. Multiple-gestation pregnancies

Multiple-gestation pregnancies will be enrolled in the registry and included in the analysis population; however, for the analyses of preterm birth, SGA, and postnatal growth deficiency, multiple-gestation pregnancies will be excluded from the analysis population due to the higher risk of these outcomes in twins and higher-order multiples.

9.7.2. Descriptive characteristics

Patient characteristics (including the covariates listed in [Section 9.3.5](#)) will be summarized with descriptive statistics for each cohort.

The number of observations, median, mean, standard deviation, minimum, and maximum will be reported for each continuous variable. The frequency and percentage per category will be reported for each categorical variable.

If adequate sample size is achieved for comparative analyses (see [Section 9.5.4](#)), balance between the cohorts will be assessed by calculating the standardized mean differences for all covariates, comparing the ritlecitinib-exposed and comparator cohorts. These standardized mean differences will be presented before and after inverse probability of treatment weighting (IPTW).

9.7.3. Outcome prevalence

The unit of analysis is the pregnancy because some individuals may enroll more than one pregnancy in the registry.

Prevalence of the outcomes of interest will be calculated according to the conventions described in Table 5. In general, the prevalence of each outcome will be calculated by dividing the number of cases of the outcome by the appropriate denominator for that particular outcome, based on clinical knowledge.

For most outcomes, the analysis population (denominator) will be the number of pregnancies with outcome data, the number of live births, or the number of infants with follow-up data at the timepoint of interest, as appropriate; however, for some outcomes, the analysis population (denominator) will be restricted based on certain relevant factors (as noted in Table 5).

Table 5. Outcome Prevalence Calculations

Outcome	Numerator (among those in denominator)	Denominator	Relevant etiologic period (timing of exposure assessment)
MCM	Live births with confirmed (ie, adjudicated) MCMs (excluding MCMs not associated with medication exposure)	Live births	First trimester
MCM sensitivity analysis (see Section 9.7.7.2)	Live births and fetal losses with confirmed MCMs (excluding MCMs not associated with medication exposure)	Live births and fetal losses	First trimester
SAB	Spontaneous abortions	Pregnancies with outcome data who are enrolled before 20 completed gestational weeks	Before 20 completed gestational weeks
Pregnancy termination	Pregnancy terminations	Pregnancies with outcome data	Before 20 completed gestational weeks
Pre-eclampsia	Pregnancies with pre-eclampsia	Pregnancies with outcome data	Full pregnancy period
Eclampsia	Pregnancies with eclampsia	Pregnancies with outcome data	Full pregnancy period
Gestational diabetes	Pregnancies with gestational diabetes	Pregnancies with outcome data	Full pregnancy period
Pregnancy-induced hypertension	Pregnancies with pregnancy-induced hypertension	Pregnancies with outcome data	Full pregnancy period

Table 5. Outcome Prevalence Calculations

Outcome	Numerator (among those in denominator)	Denominator	Relevant etiologic period (timing of exposure assessment)
Stillbirth	Stillbirths	Pregnancies with outcome data	Full pregnancy period
Preterm birth	Preterm births	Singleton live births without confirmed MCM among pregnant individuals who are enrolled before 37 completed gestational weeks	Before 37 completed gestational weeks
SGA	SGA births	Singleton live births without confirmed MCM with weight data	Full pregnancy period
Minor congenital malformations	Live births with minor congenital malformation	Live births	Full pregnancy period
Infant serious infection	Infants with a qualifying infection	Live births	From birth to 1 year of age
Infant hospitalization	Infants with a qualifying hospitalization	Live births	From birth to 1 year of age
Infant death	Infant deaths	Live births	From birth to 1 year of age
Postnatal growth deficiency (at 2, 4, 6, and 12 months)	Infants with postnatal growth deficiency	Singleton live births without confirmed MCM, preterm birth, or SGA with weight/length/head circumference data at the specified timepoint	Full pregnancy period
Infant developmental delay (at 2, 4, 6, and 12 months)	Infants with developmental delay	Live births without confirmed MCM or preterm birth with developmental milestone data for the category at the specified timepoint	Full pregnancy period

MCM = major congenital malformation; SAB = spontaneous abortion; SGA = small-for-gestational-age.

9.7.4. Comparative analyses

Comparative analyses will be conducted for MCM and, if sample size permits, for each of the secondary outcomes. Crude (unadjusted) RRs (and corresponding 95% CIs) will be calculated using Exact methods. Adjusted RRs will be calculated using generalized linear models (binomial family) with a log (RR) link and weighted by IPTW (Desai and Franklin 2019). The Clopper-Pearson method will be used to derive 95% CIs.

9.7.4.1. Propensity score modeling

IPTW will be calculated using propensity scores estimated from propensity score models (Desai and Franklin 2019). Each individual's propensity score (the probability of being in the exposed cohort, given membership in the study population [either cohort]) will be estimated using a logistic regression model with exposure status as the outcome (dependent variable). The covariates listed in Section 9.3.5 will be considered for inclusion in the model as

independent (predictor) variables. Only covariate information from prior to pregnancy start (conception) will be included in propensity score models. Each variable will be carefully considered by the investigators to ensure that only potential risk factors (and therefore potential confounders) for the study outcomes are included in the final propensity score model.

Stabilized weights will be estimated with trimming at the first and 99th percentiles to minimize the impact of any extreme weights (Stuart 2010; Hernán and Robbins 2020). One propensity score model will be developed that includes all participants in the study cohorts (ie, ritlecitinib-exposed and comparators). Hence, each participant will have one estimated propensity score for all analyses.

9.7.5. Subgroup analyses

If sample size permits, subgroup analyses will be conducted that consider:

- Timing of exposure (pre-conception or earliest trimester of exposure)
- Extent of exposure (cumulative dose during pregnancy)
- Duration of exposure (cumulative duration during pregnancy or relevant exposure window)
- Maternal age group at conception (15 to <18, 18 to <35, 35 to <45, and ≥45 years)
- AA severity (mild, moderate, severe)
- System organ class of the defect (MCM outcome only)

9.7.6. Supplementary analyses

Supplementary analyses will be conducted that include pregnant individuals who were excluded from the analysis population due to:

- Occurrence of the pregnancy outcome prior to enrollment (retrospectively enrolled participants)
- Exposure to a known teratogen or an investigational medication during pregnancy (teratogen/investigational medication-exposed participants)
- Exposure to non-ritlecitinib JAK or TEC kinase inhibitors during pregnancy (comparator cohort)

9.7.7. Sensitivity analyses

The following sensitivity analyses will also be conducted to examine the extent to which changes in certain methods or assumptions affect the results, if sample size permits, and presented in the final study report.

9.7.7.1. Definition of prospective enrollment

As described in [Section 9.7.1.2](#), a sensitivity analysis of MCM will be conducted that applies a stricter definition of prospective enrollment. For this analysis, individuals who enroll prior

to diagnostic prenatal testing (eg, ultrasound to scan for structural defects at approximately 20 gestational weeks, chorionic villus sampling, and amniocentesis) will be considered prospectively enrolled, and individuals who enroll after diagnostic prenatal testing, regardless of the results, will be considered retrospectively enrolled. The outcomes of individuals who enroll prior to diagnostic prenatal testing will be compared with those of individuals who enrolled after diagnostic prenatal testing.

9.7.7.2. Inclusion of fetal losses in MCM denominator

As described in Table 5, a sensitivity analysis will be conducted that broadens the MCM denominator to include fetal losses in addition to live births.

9.7.7.3. Restriction of exposed cohort to participants exposed to ritlecitinib only

The ritlecitinib-exposed cohort will be restricted to the subset of patients who are exposed to ritlecitinib only, and no other AA treatments during pregnancy.

9.7.7.4. Restriction of comparator cohort to treated participants only

The comparator cohort will be restricted to the subset of individuals exposed to at least one AA therapy. As noted in [Section 9.2.4](#), this will be the main analysis rather than a sensitivity analysis if adequately powered.

9.7.7.5. Exclusion of participants exposed to potential teratogens

A sensitivity analysis will be conducted that excludes participants exposed to potential teratogens for the treatment of AA (eg, simvastatin and finasteride).

9.7.8. Missing data

The frequency and percentage of participants with missing data will be presented for each variable. Propensity scores may be calculated for all individuals, even those with missing data since the models can incorporate missing indicators. If the proportion of missing data is large, missing data methods may be considered, such as multiple imputation.

9.8. Quality control

Ensuring high quality data will be an ongoing, multi-step process involving automatic programming of edit checks for critical data variables in the EDC system as well as visual review for completeness, logic, consistency, and accuracy by the VRCC staff. As recommended in regulatory guidance documents, data collection forms are carefully designed to ensure data quality and integrity. All participant-reported data will be verified by the appropriate HCP, where possible.

9.8.1. Steering committee

A steering committee will be established to oversee the scientific affairs of the study, including its ongoing monitoring. A charter for steering committee activities, roles and responsibilities, and meeting frequency will be established following study initiation. The steering committee will be composed of recognized experts including (but not limited to) the

fields of teratology, epidemiology, maternal-fetal medicine, neonatology/pediatrics, and AA treatment. The steering committee and birth defect evaluators will be independent of one another, with the exception of the adjudication tie-breaker (who will be blinded to exposure status for any tie-breaker adjudication cases).

The steering committee will meet regularly to review the accumulated body of data from the study, including review of reported MCMs, which have been classified by independent birth defect evaluators, and other study outcomes. The steering committee will provide consultation regarding recruitment and retention strategies and will also carry out any actions required, including review and interpretation of data analyses and reports and contribute to publications of study data. In addition to the above activities, the steering committee will support the design and implementation of strategies to heighten awareness of the study and will provide consultation regarding recruitment and retention strategies.

9.9. Limitations of the research methods

This registry will aim to primarily collect data prospectively, minimizing the potential impact of recall bias. With primary data collection, rich, detailed information can be collected on participants, their pregnancies, and their infants, including information that is not routinely captured in medical records. Furthermore, direct data capture from participants and HCPs may minimize potential exposure, outcome, and covariate misclassification. Nonetheless, this study is subject to several limitations.

Many individuals avoid medications during pregnancy and the safety of ritlecitinib use in pregnancy is currently unknown. Hence, the number of enrolled ritlecitinib-exposed participants may be small, precluding the ability to calculate RRs or derive meaningful conclusions. A multi-model recruitment campaign and flexible, evolving retention strategies will aim to maximize study size ([Annex 1](#)).

Early, prospective enrollment is key to reducing recall and selection bias, however early pregnancy losses may be less likely to be included in a registry. Indeed, research suggests that 90% of pregnancies enrolled in registries result in a live birth ([Covington et al. 2010](#); [Veley et al. 2020](#)) whereas national estimates suggest up to 28% of pregnancies end in early losses (ie, approximately 70% result in a live birth) ([Rossen et al. 2018](#)).

Despite limiting the main analysis to prospectively enrolled participants, voluntary participation could still produce bias (eg, if high- or low-risk individuals are more likely to enroll). A description of participant characteristics including comorbidities and pregnancy history will help assess the extent of such possible bias.

Even with detailed primary data collection of AA therapies at multiple timepoints during pregnancy from the participants and their HCPs, exposure misclassification may still occur. For instance, the HCP report of prescription start/end dates may not accurately reflect participant's actual exposure. Further, participants will be asked to recall exposures that occurred between LMP and enrollment. To minimize this risk, data collection forms will be designed to collect detailed exposure information including drug name, dose, route, frequency of use, and start and end dates.

Some outcome risk factors (ie, potential confounders) may be unbalanced between the exposed and unexposed study cohorts. Propensity scores will be employed to statistically adjust for any baseline differences between cohorts. However, only measured covariates will be factored into the analysis and the potential for residual confounding remains due to unmeasured or poorly measured confounders.

The primary outcome, MCM, is a heterogeneous composite of any type of MCM. Individual drugs are more likely to have effects on specific MCM subtypes than all MCMs. However, the study is not powered to detect increases in the risk of individual defects.

While a sensitivity analysis is planned to assess the occurrence of MCMs in fetal losses, the condition of the lost fetus and the exact nature of the MCM may be unknown. The data collection form will retrieve any information available, but this information is expected to be limited. Therefore, outcome misclassification may be more likely to occur for MCMs among fetal losses than for MCMs among live births. Data for all the study outcomes will be reported by the HCPs to mitigate the occurrence of outcome misclassification during the study period.

To minimize loss to follow-up, retention strategies will be employed ([Section 17.7](#)) to engage the participants and HCPs and reduce the reporting burden to the extent possible. The registry will use streamlined data collection processes, simple and concise data collection forms, and provide multiple options for communication to enhance retention. Moreover, the registry staff, many of whom are obstetric nurses with expertise in data collection for research-naïve participants, will maximize retention through building relationships. Given participation requirements are similar for the exposed and unexposed, the potential for differential loss to follow-up is expected to be low.

9.10. Other aspects

Not applicable.

10. PROTECTION OF HUMAN PARTICIPANTS

10.1. Study participant information

All parties will comply with all applicable laws, including laws regarding the implementation of organizational and technical measures to ensure protection of participant personal data. Such measures will include omitting participant names or other directly identifiable data in any reports, publications, or other disclosures, except where required by applicable laws.

Participant personal data will be stored at PPD in an electronic portal or secured in a locked room to ensure that only authorized study staff have access. PPD will implement appropriate technical and organizational measures to ensure that the personal data can be recovered in the event of disaster. In the event of a potential personal data breach, PPD shall be responsible for determining whether a personal data breach has in fact occurred and, if so, providing breach notifications as required by law.

To protect the rights and freedoms of natural persons with regard to the processing of personal data, when study data are compiled for transfer to Pfizer and other authorized parties, any participant names will be removed and will be replaced by a single, specific, numerical code. All other identifiable data transferred to Pfizer or other authorized parties will be identified by this single, patient-specific code. PPD will maintain a confidential list of participants who participated in the study, linking each participant's numerical code to their actual identity. In case of data transfer, Pfizer will maintain high standards of confidentiality and protection of participants' personal data consistent with the vendor contract and applicable privacy laws.

10.2. Participant consent

Informed consent will be obtained for each registry participant. Electronic consent will be available through the registry web-based application. Should participants prefer to enroll via phone, this registry qualifies for a waiver of documentation of informed consent. Adult participants will be given the option to provide verbal consent under the waiver of documentation of informed consent, or signed informed consent through the web-based application or via courier. Adults are defined as individuals who have attained the legal age for consenting to treatments, procedures, or clinical investigations under applicable law in various states within the US.

Minors are defined as individuals who have not attained the legal age for consenting to treatments, procedures, or clinical investigations under applicable law in various states within the US. The definitions of a minor and an emancipated minor vary by state within the US. This registry will follow applicable laws for the state in which the participant resides. If a minor requests participation in the registry and all eligibility criteria are met, the registry will obtain assent from the minor and signed written consent from a parent or guardian through the web-based application or via courier. Written consent from both parent(s) or both guardian(s) will be obtained in the US states in which this is required by local laws and regulations.

At the initial screening with potential participants, the registry web-based application or registry associate will obtain consent to collect basic information about the individual, such as age and state of residence, to determine whether the individual is a minor and to ensure that applicable local laws and regulations are followed.

10.2.1. Additional safeguards for children in clinical investigations

Although this registry involves the collection of information on infants after birth, the registry protocol will be conducted in full consideration of 21 CFR Part 50, Subpart D, Additional Safeguards for Children in Clinical Investigations (for FDA-regulated human subjects research). This registry will only ascertain maternal and infant information via maternal and pediatric HCPs, and no clinical specimens will be collected from mothers or infants; therefore, data collected on infants of individuals in this pregnancy registry involves no greater than minimal risk to the infants. While the infants will be too young to provide assent, the registry protocol will require permission from the mothers, and they will be asked to provide authorization for release of medical information from their infants' HCPs.

10.2.2. Electronic informed consent process

The website will contain information about the registry and will provide access to the study's web-based application. The individual will register with their computer or mobile device using credentials (ie, name, e-mail address, and password) via the web-based application.

Once the individual has registered, the application will automatically start the consent process. The application will present the contents of the consent in a scrollable window. The individual will review the document, and the application will present the following options: "Hold," "Disagree," and "Sign and Publish."

If the individual has questions during the consent process, they will be encouraged to stop the consenting process on the application via the "Hold" button and call the VRCC, where study specialists will assist with any questions. The individual can resume completion of the consent process at any time. If the individual does not wish to provide consent, she will be directed to choose the "Disagree" option, and the process will stop. If the participant wishes to provide consent, they will be directed to choose "Sign and Publish."

The application will provide an option for the individual to view or e-mail their completed consent form(s).

After the informed consent, the individual will complete the medical release form(s) and answer some basic medical information questions.

10.2.3. Waiver of documentation of informed consent

The following US regulations indicate that the waiver of documentation of informed consent is appropriate for this registry.

As is stated in US CFR, 21 CFR 56.109 [and additionally in 45 CFR 46.117(c)(2)]:

(c) An IRB shall require documentation of informed consent in accordance with 50.27 of this chapter, except as follows:

(1) The IRB may, for some or all subjects, waive the requirement that the subject, or the subject's legally authorized representative, sign a written consent form if it finds that the research presents no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside the research context

(d) In cases where the documentation requirement is waived under paragraph (c)(1) of this section, the IRB may require PPD to provide subjects with a written statement regarding the research.

The research involves no more than minimal risk to participants. This is an observational study that involves no experimental intervention and poses no possibility of physical harm. The only potential risk is a breach of confidentiality, and the registry has well-established

procedures in place to prevent any such breach. Extensive safeguards are in place to ensure that participants' privacy is protected:

1. An adequate plan is provided to protect the identifiers from improper use and disclosure.
2. An adequate plan is provided to remove the identifiers at the earliest opportunity.
3. Adequate assurances are provided that the protected health information will not be reused or disclosed to any other person or entity.

The research involves no procedures for which written consent is normally required outside the research context. Enrollment in this observational study will be strictly voluntary, and participants can withdraw their consent to participate at any time. The schedule of participant visits and all treatment regimens will be at the discretion of the treating HCP. Data submitted to the registry will be limited to data routinely collected and documented in the participant's medical record.

10.3. Participant withdrawal

Participants may withdraw from the study at any time at their own request, or they may be withdrawn at any time at the discretion of the PPD for safety, behavioral, or administrative reasons. In any circumstance, every effort should be made to document outcomes, if applicable. PPD would inquire about the reason for withdrawal and follow-up with the participant regarding any unresolved adverse events (AEs).

If the participant withdraws from the study and also withdraws consent for disclosure of future information, no further evaluations should be performed, and no additional data should be collected. The Sponsor may retain and continue to use any data collected before such withdrawal of consent.

10.4. IRB/Ethics Committee (EC)

It is the responsibility of PPD to have prospective approval of the study protocol, protocol amendments, materials describing the consent process (eg, statement regarding agreement to participate), and other relevant documents, (eg, recruitment advertisements), if applicable, from the IRB/EC. All correspondence with the IRB/EC should be retained by PPD. Copies of IRB/EC approvals should be forwarded to Pfizer.

10.5. Ethical conduct of the study

The study will be conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value and rigor and follow generally accepted research practices described in the following guidelines:

- Guidelines for Good Pharmacoepidemiology Practices (GPP). Public Policy Committee, International Society of Pharmacoepidemiology. *Pharmacoepidemiology and Drug Safety* 2015; 25:2-10.
<https://onlinelibrary.wiley.com/doi/full/10.1002/pds.3891>

- Postapproval Pregnancy Safety Studies: (Draft) Guidance for Industry issued by FDA
<https://www.fda.gov/media/124746/download>
- International Ethical Guidelines for Epidemiological Studies issued by the Council for International Organizations of Medical Sciences (CIOMS)
<https://cioms.ch/shop/product/international-ethical-guidelines-for-epidemiological-studies/>
- European Medicines Agency (EMA) European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology
http://www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml
- FDA Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment
<https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071696.pdf>
- FDA Guidance for Industry and FDA Staff: Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data
<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM243537.pdf>

11. MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE REACTIONS

REQUIREMENTS

Table 6 summarizes the requirements for recording safety events on the data collection form and for reporting safety events on the NIS Adverse Event Monitoring (AEM) Report Form to Pfizer Safety. These requirements are delineated for 3 types of events: 1) serious AEs; 2) non-serious AEs (as applicable); and 3) scenarios involving drug exposure, including exposure during pregnancy, exposure during breastfeeding, medication error, overdose, misuse, extravasation, lack of efficacy, and occupational exposure. These events are defined in [Section 11.3](#).

Note that serious AEs requiring adjudication by the External Adjudication Committee (ie, any malformation) are not reportable to Pfizer Safety.

Table 6. Safety Event Reporting Requirements

Safety Event	Recorded on the data collection forms	Reported on the NIS AEM Report Form to Pfizer Safety within 1 Business Day/3 Calendar Days ^a of Awareness
Serious AE	All	All ^b
Non-serious AE	All	None
Scenarios involving exposure during breastfeeding, medication	All (regardless of whether associated with an AE)	All (regardless of whether associated with an AE/serious AE)

Table 6. Safety Event Reporting Requirements

Safety Event	Recorded on the data collection forms	Reported on the NIS AEM Report Form to Pfizer Safety within 1 Business Day/3 Calendar Days ^a of Awareness
error, overdose, misuse, extravasation, lack of efficacy		Note: Any associated AE is reported together with the exposure scenario.
Scenarios involving exposure to a drug during pregnancy (EDP)	All AEs or serious AEs associated with EDP Notification of EDP alone (ie, not associated with an AE or serious AE) is not required when the study population is pregnant individuals.	All serious AEs ^b associated with EDP Notification of EDP alone (ie, not associated with a serious AE) is not required when the study population is pregnant individuals.
Scenarios involving occupational/environmental exposure	Not applicable	All (regardless of whether associated with an AE/serious AE)

AE = adverse event; AEM = adverse event monitoring; EDP = exposure to a drug during pregnancy; NIS = non-interventional study

a Whichever is shorter. If a national or state holiday falls directly before or after a weekend (resulting in ≥ 3 consecutive calendar days of closure), the reporting will be done the next business day.

b Except for serious AEs judged by the External Adjudication Committee [ie, any malformations]). Of note, adjudicated serious AEs of which an HCP has indicated the serious AE to have a causal relationship with ritlecitinib or other treatments of AA are not included within this exception and must be reported to Pfizer Safety.

For each safety event, the PPD VRCC must pursue and obtain adequate information to determine the outcome and to assess whether it meets the criteria for classification as a serious AE (refer to [Section 11.3.2 Serious Adverse Events](#)).

Safety events must be reported per the process noted in Table 6 **regardless of whether the event is determined by the HCP to be related to ritlecitinib**. In particular, if the serious AE is fatal or life-threatening, notification to Pfizer must be made immediately, irrespective of the extent of available event information. The timeframe noted in Table 6 also applies to additional, new (follow-up) information on previously forwarded safety event reports. In the rare situation that the PPD VRCC does not become immediately aware of the occurrence of a reportable safety event, the PPD VRCC must report the event within 1 business day/ 3 calendar days after learning of it and document the time of first awareness of the events on the NIS AEM Report Form.

For all safety events that are mentioned in the far-right column of Table 6, the PPD VRCC is obligated to pursue and to provide any additional information to Pfizer with the same reporting timeline. In addition, the PPD VRCC may be requested by Pfizer to obtain specific follow-up information in an expedited fashion. This information is more detailed than that recorded on the data collection forms. In general, this will include a description of the safety

PFIZER CONFIDENTIAL

event in sufficient detail to allow for a complete medical assessment of the case and independent determination of possible causality. Any information relevant to the event, such as concomitant medications and illnesses, must be provided. In the case of a patient death, a summary of available autopsy findings must be submitted as soon as possible to Pfizer or its designated representative.

This protocol will use an External Adjudication Committee wherein, to maintain scientific integrity, and adjudication of some clinical endpoints (ie, any malformations) defined in the study objectives will be performed. The External Adjudication Committee is responsible for ongoing analysis of any malformations and of their adjudication as endpoints. Any malformation that is not adjudicated as an endpoint by the External Adjudication Committee is reportable and is forwarded to Pfizer Safety. In addition, when the HCP has judged a malformation to have a causal relationship with ritlecitinib or other medications used to treat AA, the PPD VRCC must still report it to Pfizer Safety, even if that event is a component of the adjudicated endpoint.

11.1. Reporting period

For each patient, the reporting period will begin at the time of the patient's first dose of ritlecitinib or other medications used to treat AA, or the time of the patient's informed consent if she is being treated with ritlecitinib or other medications used to treat AA at study start, and lasts through the end of the observation period of the study, which must include at least 28 calendar days following the last administration of the drug under study; a report must be submitted to Pfizer Safety (or its designated representative) for any safety events (as per Table 6) occurring during this period. If a patient is administered ritlecitinib or other medications used to treat AA on the last day of the observation period, then the reporting period should be extended for 28 calendar days following the end of observation. Most often, the date of informed consent is the same as the date of enrollment. In some situations, there may be a lag between the dates of informed consent and enrollment. In these instances, if a patient provides informed consent but is never enrolled in the study (eg, patient changes his/her mind about participation, failed screening criteria), the reporting period ends on the date of the decision to not enroll the patient.

If the PPD VRCC becomes aware of a serious AE occurring at any time after completion of the study and the serious AE has been reported as related to ritlecitinib or other medications used to treat AA, the serious AE must also be reported to Pfizer Safety.

11.2. Causality assessment

An HCP's causality assessment is the determination of whether there exists a reasonable possibility that ritlecitinib or other medications used to treat AA caused or contributed to the safety event. For all safety events, sufficient information should be obtained by the investigator to determine the causality.

In this study, unlike a trial design with sites and investigators, reporting HCPs will not have received formal training on providing causality assessments for the study drug. Further, given limited known information about the safety of ritlecitinib in pregnancy, it is expected that the

HCPs will rarely provide a causality assessment for the reportable safety events, or they will report it as “unknown” as s/he cannot determine it. In this event, the applicable, reportable safety event must still be reported to Pfizer Safety per the process outlined in Table 6.

If the HCP cannot determine the etiology of the event but s/he determines that ritlecitinib or other medications used to treat AA did not cause the event, this should be clearly documented on the data collection forms and the NIS AEM Report Form.

For all safety events with a causal relationship to ritlecitinib or other medications used to treat AA, follow-up by the PPD VRCC is required until the event and/or its sequelae resolve or stabilize at a level acceptable to the PPD VRCC, and Pfizer concurs with that assessment.

11.3. Definitions of safety events

11.3.1. Adverse events

An AE is any untoward medical occurrence in a patient administered a medicinal product. The event need not necessarily have a causal relationship with the product treatment or usage. Examples of AEs include but are not limited to:

- Abnormal test findings (see below for circumstances in which an abnormal test finding constitutes an AE)
- Clinically significant signs and symptoms
- Changes in physical examination findings
- Hypersensitivity
- Progression/worsening of underlying disease
- Lack of efficacy
- Drug abuse
- Drug dependency

Additionally, for medicinal products, they may include the signs or symptoms resulting from:

- Drug overdose
- Drug withdrawal
- Drug misuse
- Off-label use
- Drug interactions
- Extravasation
- Exposure during pregnancy
- Exposure during breastfeeding
- Medication error
- Occupational exposure

Abnormal test findings

The criteria for determining whether an abnormal objective test finding should be reported as an AE are as follows:

- Test result is associated with accompanying symptoms
- Test result requires additional diagnostic testing or medical/surgical intervention
- Test result leads to a change in study dosing or discontinuation from the study, significant additional concomitant drug treatment, or other therapy
- Test result is considered to be an AE by the HCP or Sponsor

Merely repeating an abnormal test, in the absence of any of the above conditions, does not constitute an AE. Any abnormal test result that is determined to be an error does not require reporting as an AE.

11.3.2. Serious adverse events

A serious AE is any untoward medical occurrence in a patient administered a medicinal or nutritional product (including pediatric formulas) at any dose that:

- Results in death
- Is life-threatening
- Requires inpatient hospitalization or prolongation of hospitalization (see below for circumstances that do not constitute serious AEs)
- Results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions)
- Results in congenital anomaly/birth defect

Medical and scientific judgment is exercised in determining whether an event is an important medical event. An important medical event may not be immediately life-threatening and/or result in death or hospitalization. However, if it is determined that the event may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above, the important medical event should be reported as serious.

Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; or development of drug dependency or drug abuse.

Additionally, any suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, is considered serious. The event may be suspected from clinical symptoms or laboratory findings indicating an infection in a patient exposed to a Pfizer product. The terms “suspected transmission” and “transmission” are considered synonymous. These cases are considered unexpected and handled as serious expedited cases by pharmacovigilance personnel. Such cases are also considered for reporting as product defects, if appropriate.

Hospitalization

Hospitalization is defined as any initial admission (even if less than 24 hours) to a hospital or equivalent healthcare facility or any prolongation to an existing admission. Admission also includes transfer within the hospital to an acute/intensive care unit (eg, from the psychiatric wing to a medical floor, medical floor to a coronary care unit, neurological floor to a tuberculosis unit). An emergency room visit does not necessarily constitute a hospitalization; however, an event leading to an emergency room visit should be assessed for medical importance.

Hospitalization in the absence of a medical AE is not in itself an AE and is not reportable. For example, the following reports of hospitalization without a medical AE are not to be reported:

- Social admission (eg, patient has no place to sleep)
- Administrative admission (eg, for yearly exam)
- Optional admission not associated with a precipitating medical AE (eg, for elective cosmetic surgery)
- Hospitalization for observation without a medical AE
- Admission for treatment of a pre-existing condition not associated with the development of a new AE or with a worsening of the pre-existing condition (eg, for work-up of persistent pre-treatment lab abnormality)

11.3.3. Scenarios necessitating reporting to Pfizer Safety within 1 business day/ 3 calendar days

Scenarios involving exposure during pregnancy (EDP), exposure during breastfeeding, medication error, overdose, misuse, extravasation, lack of efficacy, and occupational exposure are described below.

Exposure during pregnancy

An EDP occurs if:

- A female becomes, or is found to be, pregnant while receiving or having been exposed to the drugs under study, or the female becomes, or is found to be, pregnant after discontinuing and/or being exposed to the drugs under study (*maternal exposure*)
- A female nonparticipant is found to be pregnant while being exposed or having been exposed to study intervention because of occupational or environmental exposure (eg, a female family member or HCP reports that she is pregnant and has been exposed to the product)

This information must be submitted to Pfizer Safety following the same reporting timeline and using the NIS AEM Report Form and the EDP Supplemental Form. Prospective and

retrospective EDP reports are reportable to Pfizer Safety following the requirement described in Table 6.

All reports submitted should include the anticipated date of delivery, as applicable, and should be managed as follows:

- Follow-up is conducted to obtain general information on the pregnancy; in addition, follow-up is conducted to obtain information on EDP outcome for all EDP reports with pregnancy outcome unknown.
- A pregnancy is followed until completion or until pregnancy termination (eg, induced abortion) and Pfizer is notified of the outcome. This information is provided as a follow-up to the initial EDP report.
- In the case of a live birth, the structural integrity of the neonate can be assessed at the time of birth.
- In the event of a termination, the reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by gross visual inspection (unless pre-procedure test findings are conclusive for a congenital anomaly and the findings are reported).

If the outcome of the pregnancy meets the criteria for a serious AE (eg, ectopic pregnancy, SAB, intrauterine fetal demise, neonatal death, or congenital anomaly [in a live born, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the procedures for reporting serious AEs should be followed.

Additional information about pregnancy outcomes that are reported as serious AEs follows:

- SAB includes miscarriage and missed abortion
- Neonatal deaths that occur within 1 month of birth should be reported, without regard to causality, as serious AEs. In addition, infant deaths after 1 month should be reported as serious AEs when the investigator assesses the infant death as related or possibly related to exposure to investigational product.

Additional information regarding the EDP may be requested. Further follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on preterm infants to identify developmental delays).

For NIS conducted in pregnant individuals, data on the pregnancy outcome and non-serious AEs are expected to be collected and analyzed in the study database. In such instances, only EDPs associated with a serious AE are to be reported.

Exposure during breastfeeding

Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of an associated AE. An exposure during breastfeeding report is not created when a Pfizer drug specifically approved for use in breastfeeding individuals (eg, vitamins) is administered in

accord with authorized use. However, if the infant experiences an AE associated with such a drug's administration, the AE is reported together with the exposure during breastfeeding.

Medication error

A medication error is any unintentional error in the prescribing, dispensing, or administration of a medicinal product that may cause or lead to inappropriate medication use or patient harm while in the control of the HCP, patient, or consumer. Such events may be related to professional practice, healthcare products, procedures, and systems, including prescribing; order communication; product labeling, packaging, and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use.

Medication errors include:

- Near misses, involving or not involving a patient directly (eg, inadvertent/erroneous administration, which is the accidental use of a product outside of labeling or prescription on the part of the HCP or the patient/consumer)
- Confusion with regard to invented name (eg, trade name, brand name)

The PPD VRCC must submit the following medication errors to Pfizer Safety, irrespective of the presence of an associated AE/serious AE:

1. Medication errors involving patient exposure to the product, whether or not the medication error is accompanied by an AE
2. Medication errors that do not involve a patient directly (eg, potential medication errors or near misses)
 - When a medication error does not involve patient exposure to the product, the following minimum criteria constitute a medication error report:
 - An identifiable reporter
 - A suspect product
 - The event medication error

Overdose, misuse, extravasation

Reports of overdose, misuse, and extravasation associated with the use of a Pfizer product are reported to Pfizer Safety by the PPD VRCC, irrespective of the presence of an associated AE/serious AE.

Lack of efficacy

Reports of lack of efficacy of a Pfizer product are reported to Pfizer Safety by the PPD VRCC, irrespective of the presence of an associated AE/serious AE or the indication for use of the Pfizer product.

Occupational/Environmental exposure

Reports of occupational exposure are reported to Pfizer Safety by the PPD VRCC, irrespective of the presence of an associated AE/serious AE.

Since the information about the occupational exposure does not pertain to a participant enrolled in the study, the information is not recorded on a data collection form; however, a copy of the completed NIS serious AE Report Form must be maintained in the PPD VRCC files.

12. PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS

In the event of any prohibition or restriction imposed (eg, clinical hold) by an applicable competent authority in any area of the world, or if PPD is aware of any new information which might influence the evaluation of the benefits and risks of a Pfizer product, Pfizer should be informed immediately.

In addition, PPD will inform Pfizer immediately of any urgent safety measures taken by PPD to protect the study participants against any immediate hazard, and of any serious breaches of this NIS protocol of which PPD becomes aware.

The registry will produce 8 annual interim reports starting in 2026 and a final comprehensive study report will be developed after the conclusion of the registry.

The annual interim reports will present the registry design, methodology, and results to date, including the number of enrolled participants, their demographics and characteristics, and their outcomes, by study cohort. As needed, strategies will be considered to support increased enrollment and improved representativeness.

The final comprehensive study report will present the results of the full statistical analysis (described in [Section 9.7](#)) as well as an interpretive discussion of the results.

The annual interim and final study reports will be submitted to the relevant regulatory agencies. Submissions to scientific congresses and/or to peer-reviewed journals are planned. Additionally, this study will be disclosed and registered in the Heads of Medicines Agencies-European Medicines Agency (HMA-EMA) catalogue of real-world data sources and studies.

13. REFERENCES

American Academy of Pediatrics (AAP). Recommendations for preventive pediatric health care. 2022. https://downloads.aap.org/AAP/PDF/periodicity_schedule.pdf. Updated March 2021. Accessed 05 April 2023.

American College of Obstetricians and Gynecologists (ACOG). Committee Opinion No 700: methods for estimating the due date. *Obstet Gynecol*. 2017. 129(5):e150-4.

American College of Obstetricians and Gynecologists (ACOG). Clinical management guidelines for obstetrician-gynecologists: gestational hypertension and preeclampsia. *Obstet Gynecol*. 2020a. Jun;135(6):e237-e260.

American College of Obstetricians and Gynecologists (ACOG). Management of stillbirth: obstetric care consensus No, 10. *Obstet Gynecol*. 2020b. Mar;135(3):e110-e132.

Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. *BMJ*. 2013. Nov;347:f6564.

Battaglia FC, Lubchenco LO. A practical classification of newborn infants by weight and gestational age. *J Pediatr*. 1967. 71(2):159-63.

Benigno M, Anastassopoulos KP, Mostaghimi A, et al. A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States. *Clin Cosmet Investig Dermatol* 2020;13:259-266.

Butwick AJ, Druzin ML, Shaw GM, Guo N. Evaluation of US State-Level Variation in Hypertensive Disorders of Pregnancy. *JAMA Netw Open*. Oct 1 2020;3(10):e2018741.

Centers for Disease Control and Prevention (CDC). Update on overall prevalence of major birth defects—Atlanta, Georgia, 1978-2005. *MMWR Morb Mortal Wkly Rep*. 2008. Jan 11;57(1):1-5.

Centers for Disease Control and Prevention (CDC). National Center for Health Statistics. WHO growth standards are recommended for use in the U.S. for infants and children 0 to 2 years of age. Updated September 2010. https://www.cdc.gov/growthcharts/who_charts.htm Accessed 23 August 2023.

Centers for Disease Control and Prevention (CDC), Division of Birth Defects and Developmental Disabilities. Birth defects toolkit. Appendix B: external minor congenital anomalies. Updated November 2019. www.cdc.gov/ncbddd/birthdefects/surveillancemanual/appendices/appendix-b.html. Accessed 23 August 2023.

Centers for Disease Control and Prevention (CDC). Birth defects surveillance toolkit. 1.4 Congenital anomalies – definitions. Updated November 2020. www.cdc.gov/ncbddd/birthdefects/surveillancemanual/chapters/chapter-1/chapter1-4.html. Accessed 23 August 2023.

Centers for Disease Control and Prevention (CDC), National Center on Birth Defects and Developmental Disabilities. CDC/BPA 6-digit code for Congenital Anomalies. Updated 2021. <https://www.cdc.gov/ncbddd/birthdefects/macdp.html#CaseDefinition>. Accessed 23 August 2023.

Centers for Disease Control and Prevention (CDC). CDC's developmental milestones. Updated 2023. www.cdc.gov/ncbddd/actearly/milestones/index.html. Accessed 23 August 2023.

Cho SI, Yu D-A, Kim SI, Lee SM, Kwon O. Pregnancy outcomes in female patients with alopecia areata: a nationwide population-based study. *Journal of Investigative Dermatology*. 2021. 141:1844-1847.

Council for International Organizations of Medical Sciences (CIOMS). CIOMS Cumulative Pharmacovigilance Glossary Version 1.0. 2021. <https://cioms.ch/wp-content/uploads/2021/03/CIOMS-Cumulative-PV-Glossary-v1.0.pdf>. Accessed 23 March 2023.

Covington DL, MH, Churchill P, et al. Improving accuracy in enrollment targets for pregnancy registries. *Pharmacoepidemiol Drug Saf*. 2010. 19(1):S71-72.

Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. *BMJ*. 2019. Oct 23;367:l5657.

Eltonsy S, Martin B, Ferreira E, et al. Systematic procedure for the classification of proven and potential teratogens for use in research. *Birth Defects Res A Clin Mol Teratol*. 2016 Apr;106(4):285-97.

Ely DM, Driscoll AK. Infant mortality in the United States, 2019: Data from the period linked birth/infant death file. *Natl Vital Stat Rep*. 2021;70(14):1-18.

Feldkamp ML, Botto LD, Carey JC. Reflections on the etiology of structural birth defects: Established teratogens and risk factors. *Birth Defects Res A Clin Mol Teratol*. Aug 2015;103(8):652-5.

Food and Drug Administration (FDA). Ritlecitinib NDA approval letter. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/216386Orig1s000ltr.pdf. Accessed 15 August 2023.

FDA. Postapproval Pregnancy Safety Studies Guidance for Industry DRAFT GUIDANCE (May 2019). <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-pregnancy-safety-studies-guidance-industry>. Accessed 05 April 2023.

Hernán M, Robins J. IP weighting and marginal structural models (chapter 12). In: *Causal inference: what if*. Boca Raton: CRC Press; 2020. <https://cdn1.sph.harvard.edu/wp->

content/uploads/sites/1268/2022/12/hernanrobins_WhatIf_20dec22.pdf. Accessed 05 April 2023.

Holmes LB, Westgate MN. Inclusion and exclusion criteria for malformations in newborn infants exposed to potential teratogens. *Birth Defects Res A Clin Mol Teratol*. 2011. Sep;91(9):807-12.

Jatlaoui TC, Eckhaus L, Mandel MG, et al. Abortion Surveillance - United States, 2016. *MMWR Surveill Summ*. 2019. Nov 29;68(11):1-41.

LITFULO™ label. Pfizer, Inc. June 2023.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf. Accessed 15 August 2023.

LITFULO™ letter. FDA June 2023.
https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2023/215830Orig1s000ltr.pdf. Accessed 15 August 2023.

MacDorman MF, Gregory EC. Fetal and perinatal mortality: United States, 2013. *Natl Vital Stat Rep*. 2015;64(8):1-24.

Martin JA, Hamilton BE, Osterman MJK, Driscoll AK. Births: final data for 2019. *Natl Vital Stat Rep*. 2021. Apr;70(2):1-51.

Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study part II: Results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata. *J Amer Acad Dermatol*. June 2021;84(6): 1594-1601.

Mostaghimi A, Gao W, Ray M et al. Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population. *JAMA Dermatol* 2023. Epub 01 March 2023.

Osterman MJK, Hamilton BE, Martin JA, et al. Births: final data for 2020. *Natl Vital Stat Rep*. 2022. Feb;70(17):1-50.

Polifka JE, Friedman JM. Medical genetics: 1. Clinical teratology in the age of genomics. *CMAJ*. Aug 6 2002;167(3):265-73.

PPD pregnancy and lactation studies. <https://www.ppd.com/our-solutions/clinical/peri-and-post-approval/non-interventional-studies/pregnancy-and-lactation-studies/>. Accessed 19 July 2023.

Pratt CH, King LE Jr, Messenger AG, et al. Alopecia areata. *Nat Rev Dis Primers* 2017;3:17011.

Quintanilla Rodriguez BS, Mahdy H. Gestational diabetes. In: *StatPearls*. Treasure Island, FL: StatPearls Publishing; 2024.

Rosenberg SA, Zhang D, Robinson CC. Prevalence of developmental delays and participation in early intervention services for young children. *Pediatrics*. 2008. 121(6): e1503-e1509.

Rossen LM, Ahrens KA, Branum AMJP. Epidemiology p. trends in risk of pregnancy loss among US women, 1990–2011. *Paediatr Perinat Epidemiol*. 2018. 32(1):19-29.

Senna M, Ko J, Tosti A, et al. Alopecia areata treatment patterns, healthcare resource utilization, and comorbidities in the US population using insurance claims. *Advances In Therapy*. 2021. 38:4646-4658.

Stuart EA. Matching methods for causal inference: a review and a look forward. *Stat Sci*. 2010. Feb 1;25(1):1-21.

TERIS. Teratogen Information System; Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington. Website. 2021. <https://deohs.washington.edu/teris/>. Accessed 07 June 2023.

US Census Bureau. Age and Sex (S0101): 2021: ACS 5-Year Estimates Subject Tables. In: 2017-2021 American Community Survey 5-Year Estimates. <https://data.census.gov/table?q=S0101&tid=ACSST5Y2021.S0101>. Accessed 07 August 2023.

Veley K CD, Buus R, Chan RL, Churchill P. Sample size calculations for pregnancy. *Pharmacoepidemiol Drug Saf*. 2020. 29(3):537-538.

Villar J, Ismail LC, Victora CG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. *Lancet*. 2014. 384(9946):857-68.

Villar J, Giuliani F, Fenton TR, et al. INTERGROWTH-21st very preterm size at birth reference charts. *Lancet*. 2016. 387(10021):844-5.

Winthrop KL, Novosad SA, Baddley JW, et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. *Ann Rheum Dis*. 2015;74(12):2107-2116.

Wu P, Velez Edwards DR, Gorrindo P, et al. Association between first trimester antidepressant use and risk of spontaneous abortion. *Pharmacotherapy*. 2019. Sep;39(9):889-898.

Zomerdijk IM, Ruiter R, Houweling LMA, et al. Dispensing of potentially teratogenic drugs before conception and during pregnancy: a population-based study. *BJOG*. 2015;122(8):1119-29.

14. LIST OF TABLES

Table 1.	Outcome Definitions and Ascertainment.....	21
Table 2.	Summary of Data Collection Forms	28
Table 3.	Precision-based Sample Size Calculations	31
Table 4.	RR-based Sample Size Calculations.....	32
Table 5.	Outcome Prevalence Calculations	37
Table 6.	Safety Event Reporting Requirements.....	46
Table 7.	List of AA Therapies	65
Table 8.	Information Collected at Enrollment	68
Table 9.	Information Collected at End of Second Trimester	70
Table 10.	Information Collected at Pregnancy Outcome	71
Table 11.	Information Collected at Pediatric Follow-up	72
Table 12.	Targeted Follow-up after Event of Interest Reported.....	72

15. LIST OF FIGURES

Figure 1.	Data Collection Schedule	27
-----------	--------------------------------	----

16. LIST OF STAND ALONE DOCUMENTS

17. ANNEX 1. RECRUITMENT AND RETENTION STRATEGY

17.1. Recruitment strategy

An active, targeted, multi-pronged recruitment campaign will be employed to recruit participants for the registry. The campaign will focus on:

- Pregnant individuals
- Patients with AA
- Patients using ritlecitinib or other AA therapies
- Obstetric HCPs
- HCPs who are likely to treat patients with AA
- HCPs who are likely to prescribe ritlecitinib or other AA therapies

Obstetric HCPs and HCPs who are likely to treat patients with AA may be identified via HCP directories and/or professional associations. Pregnant individuals, patients with AA, and patients using ritlecitinib or other AA therapies may be identified through patient support groups, social media, and external data sources (eg, pharmacy claims or electronic medical records). Pfizer's existing infrastructure for supporting stakeholders (eg, the Pfizer medical information call center and patient support program) may be leveraged to identify HCPs who are known to prescribe ritlecitinib and pregnant individuals who are using ritlecitinib.

A multi-modal approach will be used to deliver registry education and recruitment materials to targeted HCPs and patients. This approach involves direct-to-HCP outreach as well as online and print advertising directed to HCPs and patients. In addition, stakeholders may be identified and provided information regarding the registry via telephone through the Pfizer medical information call center, specialty pharmacies that dispense ritlecitinib, and the patient support program.

17.2. Diversity

Study materials (eg, study website, data collection forms, information sheet, and informed consents) will be available in US English and US Spanish. In addition, a translation vendor will be available to engage in real-time translation for existing and potential participants. Campaign materials will also depict a diversity of individuals and families. Efforts will be made to recruit a patient population that is representative of the racial and ethnic distribution of individuals with AA.

17.3. Direct-to-HCP outreach

Direct-to-HCP outreach may be achieved by delivering recruitment materials to targeted HCPs via e-mail, fax, and/or hardcopy mail. In addition, Pfizer's representatives may provide registry education and recruitment materials to HCPs in person. HCPs will be asked to identify potential registry participants and encourage their participation by speaking to them about the registry and providing them with the patient-directed registry recruitment materials.

17.4. Digital advertising

Information regarding the registry and the registry recruitment materials will also be available online. A registry-specific website will be developed, where recruitment materials will be available for download. This website will be accessible through the LITFULO consumer and HCP product websites and discoverable in any internet browser by performing a search related to pregnancy, LITFULO or ritlecitinib, and/or AA. Information regarding the registry and/or a link to the registry website will also be available on the following websites:

- FDA listing of pregnancy registries on www.fda.gov, HMA-EMA catalogue of real-world data sources and studies
- Pfizer/LITFULO website
- PPD website (<https://www.ppd.com/our-solutions/clinical/peri-and-post-approval/non-interventional-studies/pregnancy-and-lactation-studies/>)

A web-based interface compatible with computers and mobile devices will also be developed to improve information accessibility and enable broader participation. As deemed necessary, online advertisements on social media sites or other relevant websites (eg, professional association websites or websites commonly visited by pregnant individuals or AA patients) may be used to direct potential participants to the registry website.

The registry plans to partner with BabyCenter (worldwide), a leading digital resource, to aid in recruitment. This resource is one of the most commonly used digital resources for pregnant individuals, reaching more than 90% of first-time expectant individuals in the US and more than 13 million monthly visitors. They are committed to providing pregnancy and parenting information worldwide via website and mobile application. The content is evidence-based and includes a wealth of information for parents and pregnant individuals, including tools to track pregnancy and baby's growth, answers to common questions regarding pregnancy and childbirth, and online communities to connect with other pregnant individuals, moms, and dads. Because it is already used by so many pregnant individuals, it is an ideal means to help recruit participants into the registry.

17.5. Print advertising

Various print materials will also be used to provide information related to the registry and to facilitate recruitment. The LITFULO prescribing information will provide registry information, including contact information. Information related to the registry may also be directed to HCPs via announcements/publications in relevant professional journals/newsletters or presentations/exhibits at relevant professional meetings. As deemed necessary, print advertisements in newspapers or magazines with targeted patients among their readership may be used to direct potential participants to the registry, and recruitment materials may be distributed to locations commonly frequented by targeted patients (eg, ultrasound clinics).

17.6. Recruitment materials

In addition to the registry information in the product label, educational materials designed to elicit interest in registry participation will be developed. All messaging will be aligned with the product label. Materials may include the following:

- An information sheet and/or brochure that will briefly describe the registry purpose and procedures, including the incentives for participation
- Information on how to access the registry web-based application
- Registration form and sample participant consent form
- Participant consent-to-contact card (this card enables the VRCC to contact the potential participant and provide additional information about the registry)

17.7. Retention strategy

A retention strategy will be facilitated by engaging the participant and HCP and seeks to minimize the reporting burden on these groups to the extent possible.

The registry staff will serve as the first and single point of communication for registry participants and HCPs. The specialized staff, many of whom are obstetric nurses, have experience collecting data for observational studies from patients and research-naïve HCPs. They are experts at developing a rapport with HCPs and participants to facilitate data collection and build one-on-one relationships that will promote retention and reduce overall loss to follow-up. To promote HCP engagement, status updates may be shared with HCPs through various means (ie, e-mail, newsletters, and the registry website). Materials provided will emphasize the mission of the registry to promote participant engagement and point participants to the website.

The registry will use streamlined data collection processes and simple, concise data collection forms that focus on endpoints of interest to reduce the burden of reporting. The registry will provide multiple options for communication and data submission (eg, phone, fax, mail, e-mail, website, web-based application) and a flexible follow-up schedule to enhance retention and maximize data reporting.

Finally, the registry will provide compensation to participants and their HCPs who serve as data reporters. Compensation will be sent to HCPs involved in pregnant individuals' care once pregnancy outcome data have been collected. Compensation will be sent to participants once pregnancy outcome data have been collected if fetal loss occurs or once 12-month infant outcome data have been collected if live birth occurs. Compensation will be sent to pediatric HCPs once 12-month infant outcome data have been collected.

17.8. Assessment of recruitment and retention

To maximize recruitment and retention, the registry's recruitment and retention strategies will be flexible and will be continuously assessed. The registry will assess recruitment and retention by collecting information from reporters (ie, HCPs and participating individuals) on

the sources from which they received information about the registry (recruitment) and the reasons for which they ceased participation or were lost to follow-up (retention). Based on these assessments, the registry's recruitment and retention strategies will be adjusted to maximize registry participation.

18. ANNEX 2. AA TREATMENTS

This list will be updated throughout the course of the study as new products are approved.

Table 7. List of AA Therapies

Drug class	Generic name	Half-life (range)
Kinase inhibitor	Ritlecitinib	1.3 to 2.3 hours
Other Janus kinase (JAK) inhibitors	Tofacitinib	3 hours
	Baricitinib	10 hours
	Deuruxolitinib	4 hours
Oral corticosteroids	Prednisone Prednisolone Methylprednisolone Dexamethasone Betamethasone Hydrocortisone	1.5 to 72 hours
Injectable corticosteroids	Betamethasone Dexamethasone Hydrocortisone Methylprednisolone Triamcinolone	1.5 to 72 hours
Topical corticosteroids	Group I (ultra-high potency): Clobetasol propionate ointment* Augmented betamethasone dipropionate gel or ointment Diflorasone diacetate ointment Fluocinonide cream Halobetasol propionate cream or ointment Group II (high potency): Halcinonide cream* Amcinonide ointment Augmented betamethasone dipropionate cream or lotion Desoximetasone cream or gel or ointment Diflorasone diacetate cream Fluocinonide cream or gel or ointment Group III (high/medium potency): Betamethasone valerate ointment*	

Table 7. List of AA Therapies

Drug class	Generic name	Half-life (range)
	Amcinonide cream Betamethasone dipropionate cream Fluticasone propionate ointment Triamcinolone acetonide cream or ointment Group V (medium/low potency): Fluocinonide acetonide cream* Betamethasone valerate cream or lotion or foam Desoximetasone cream Fluticasone propionate cream Hydrocortisone butyrate ointment Hydrocortisone probutate cream Hydrocortisone valerate cream or ointment Mometasone furoate cream or lotion or ointment Triamcinolone acetonide cream or lotion or ointment Group VI (low potency): Fluocinolone acetonide gel* Alclometasone dipropionate cream or ointment Desonide in any vehicle Hydrocortisone butyrate Group VII (lowest potency): Dexamethasone sodium phosphate cream* Hydrocortisone acetate cream*	
Topical calcineurin inhibitor	Tacrolimus ointment	65 to 75 hours
	Pimecrolimus cream	30 to 100 hours
Topical immunotherapy	Diphenylcyclopropenone	7 days
	Squaric acid dibutylester	7 days
	Dinitrochlorobenzene	7 days
Other treatments	Anthralin	6 hours
	Psoralen plus ultraviolet A	0.5 to 2 hours
	Ultraviolet A	NA
	Panretinal photocoagulation	NA
	Vitamins	NA

PFIZER CONFIDENTIAL

Table 7. List of AA Therapies

Drug class	Generic name	Half-life (range)
	Minoxidil	3 to 4 hours
	Finasteride	6 to 8 hours
	Iron salts	
	Bimatorpost	45 minutes
	Latanoprost	2 to 3 hours
	Tretinoin	0.5 to 2 hours
	Bexarotene	7 hours
	Capsaicin	24 hours
	Sulfasalazine	5 to 10 hours
	Cyclosporine	8.5 to 27 hours
	Azathioprine	5 hours
	Excimer laser	NA
	Fractional photothermolysis laser	NA
	Simvastatin/ezetemibe	5/22 hours

NA = not applicable

*Topical corticosteroids that have been reported in the literature for the treatment of AA.

19. ANNEX 3. REGISTRY DATA COLLECTION DETAILS

19.1. Information collected at enrollment

After obtaining informed consent, the following information will be collected on the *Registration Form for Participants*, *Registration Form for Healthcare Providers*, and *Pregnancy Information Form*:

Table 8. Information Collected at Enrollment

Data	Collected from Participants	Collected from HCPs
Reporter information	- Contact information for the participant, as well as alternate contact information - HCP reporter contact information (pediatric HCP information may be provided around time of EDD if unknown at enrollment) - Request for Release of Medical Information Form(s) (form may be completed for pediatric HCP around time of EDD if unknown at enrollment)	
Registration information	- Date of consent (enrollment) - Recruitment source(s) - Minimum data for study cohort assignment: - Country of residence - Pregnancy status - AA diagnosis information - Exposure information - Prior enrollment status	- Minimum data for study cohort assignment: - Pregnancy status - AA diagnosis information - Exposure information
Maternal demographics	Maternal demographics	
Baseline pregnancy information		- First day of LMP - Method of conception
AA information		- Maternal history of AA, including date of diagnosis - Characteristics of AA, including measures of disease severity prior to pregnancy

Table 8. Information Collected at Enrollment

Data	Collected from Participants	Collected from HCPs
Maternal pre-pregnancy anthropometrics		<i>If not available from HCP, can be collected from participant</i> • Pre-pregnancy anthropometrics (weight and height)
Maternal obstetrical history		<i>If not available from HCP, can be collected from participant</i> • Number of previous pregnancies (singleton or multiple) • Outcome of all previous pregnancies • Complications of previous pregnancies • Characteristics of previous live births (preterm, SGA) • History of offspring with congenital anomalies
Family history of congenital malformations		<i>If not available from HCP, can be collected from participant</i> • Maternal and paternal history of congenital anomalies
Maternal exposures during pregnancy		• Exposure to drugs or biological products (including prescription and non-prescription drugs, dietary supplements (including folic acid and prenatal vitamins), vaccines, and known teratogens), including indication/reason for use, dose, route, frequency, and dates/duration of exposure • Exposure to tobacco, alcohol, marijuana, or recreational or illicit drugs, including timing of exposure
Ongoing pregnancy information		• Number of fetuses • EDD and method of determination • Prenatal tests performed, including type of test, date of test, and results/findings (eg, congenital malformations) • Concurrent maternal medical conditions, including but not limited to autoimmune/inflammatory disease, diabetes, hypertension, depression • Concurrent pregnancy-related maternal medical conditions or pregnancy complications

AA = alopecia areata; EDD = estimated date of delivery; HCP = healthcare provider; LMP = last menstrual period; SGA = small for gestational age

19.2. Information collected at pregnancy follow-up

At around the end of the second trimester, the HCP(s) will be asked to complete another *Pregnancy Information Form*. For participants who enroll late in pregnancy, the end of second trimester follow-up might not be applicable. In the month of the EDD, the HCP(s) will be asked to complete another *Pregnancy Information Form* as well as the *Pregnancy Outcome Form*. The participant is also contacted to provide authorization for medical release for the infant's pediatric HCP (if not previously obtained).

19.2.1. Follow-up at end of second trimester

Table 9. Information Collected at End of Second Trimester

Data	Collected from Participants	Collected from HCPs
AA information	Dates of AA during pregnancy	
Maternal exposures during pregnancy	Exposure to ritlecitinib or other AA therapies (prescription and non-prescription), including name of product, dates of exposure, and total dose taken on each day of the week, if available	- Exposure drugs or biological products (including prescription and non-prescription drugs, dietary supplements (including folic acid and prenatal vitamins), vaccines, and known teratogens), including indication/reason for use, dose, route, frequency, and dates/duration of exposure, if available - Exposure to tobacco, alcohol, marijuana, or recreational or illicit drugs, including timing of exposure, if available
Ongoing pregnancy information		- Number of fetuses - EDD and method of determination - Prenatal tests performed, including type of test, date of test, and results/findings (eg, congenital malformations) - Concurrent maternal medical conditions, including but not limited to autoimmune/inflammatory disease, diabetes, hypertension, depression - Concurrent pregnancy-related maternal medical conditions or pregnancy complications

AA = alopecia areata; EDD = estimated date of delivery; HCP = healthcare provider

19.2.2. Follow-up at pregnancy outcome

Table 10. Information Collected at Pregnancy Outcome

Data	Collected from Participants	Collected from HCPs
Disease information	Dates of AA during pregnancy	
Maternal exposures during pregnancy	Exposure to ritlecitinib or other AA therapies (prescription and non-prescription), including name of product, dates of exposure, and total dose taken on each day of the week, if available	- Exposure drugs or biological products (including prescription and non-prescription drugs, dietary supplements (including folic acid and prenatal vitamins), vaccines, and known teratogens), including indication/reason for use, dose, route, frequency, and dates/duration of exposure - Exposure to tobacco, alcohol, marijuana, or recreational or illicit drugs, including timing
Ongoing pregnancy information		- Number of fetuses - EDD and method of determination - Prenatal tests performed, including type, date, and results/findings - Concurrent maternal medical conditions, including but not limited to autoimmune disease, inflammatory disease, diabetes, hypertension, depression - Concurrent pregnancy-related maternal medical conditions or pregnancy complications
Pregnancy outcome information		- Pregnancy outcome (spontaneous abortion, pregnancy termination, live birth, stillbirth) - Date of outcome of pregnancy - Gestational age at outcome - Fetal/infant characteristics, including sex, birth weight, length, head circumference - Route of delivery - Delivery/birth complications if any 5-minute Apgar score - Congenital malformation(s) and potential contributing factors - For a fetal loss (spontaneous abortion, stillbirth), factors that may have had an impact on the loss including relevant information from postmortem findings - For pregnancy termination, reason

AA = alopecia areata; EDD = estimated date of delivery; HCP = healthcare provider

19.3. Information collected at pediatric follow-up

Timing of pediatric follow-up

If a live birth occurs, the mother is asked to provide authorization for medical release for the infant's pediatric HCP to provide follow-up information. If authorization for medical release is obtained, the pediatric HCP will be asked to complete the ***Infant Outcomes Form*** at 4 and 12 months of age. At approximately 4 months after delivery, infant data at 2 and 4 months of age will be collected; at approximately 12 months after delivery, infant data at 6 and 12 months of age will be collected. To reduce recall bias, pediatric HCPs will be asked to provide data that are routinely documented in the infants' medical records at their visits at 2, 4, 6, and 12 months of age. This schedule follows the American Academy of Pediatrics infant well-child visit schedule ([AAP 2022](#)).

Table 11. Information Collected at Pediatric Follow-up

Data	Collected from HCPs
Infant outcome information	• Date of follow-up evaluation • Age of infant • Weight, length, head circumference of infant • Developmental milestones per the HCP's assessment of normal, delayed, etc. • Congenital malformation(s) and potential contributing factors • Infant serious infection, including type and date • Infant hospitalization, including reason and date • Infant death, including date and cause of death • Infant breastfeeding and supplementary/formula feeding up to 1 year of age

HCP = healthcare provider

19.4. Targeted follow-up after report if an event of interest

If there is a congenital malformation or other event of interest, to properly characterize the event, additional information may be requested from the reporting HCP on the ***Targeted Follow-up Form***.

Table 12. Targeted Follow-up after Event of Interest Reported

Data	Collected from HCPs
Targeted follow-up information	• Details of the congenital malformation or other event of interest • Etiology • Maternal infections/conditions of relevance to event • Other information considered relevant by the HCP • Specific questions requested by the birth defect evaluator

HCP = healthcare provider

19.5. Attempts to obtain follow-up information

In the month that the follow-up is due, the HCP will be contacted and asked to provide follow-up information. If needed, 3 subsequent attempts will be made approximately every 2 weeks via various modes of communication (eg, phone, fax, e-mail, hardcopy mail). If no response is received from the HCP, additional attempts may occur at the next planned data collection timepoint. When appropriate, the participant will be asked to encourage their HCP to provide the missing data. After the 3 subsequent attempts, a final communication to obtain follow-up data will be sent to the HCP indicating that the participant will be considered lost to follow-up if no further data are received. If, at any point in the follow-up process, the participant withdraws consent or the HCP indicates that the participant is lost to follow-up, no further attempts will be made. The reason the participant was lost to follow-up (eg, no response from HCP, no response from participant, or participant withdrawal of consent) will be documented.

19.6. Follow-up process for clarification of information

For critical data points (eg, EDD, exposure, and outcome data), if there are outstanding questions, discrepancies between forms or missing data, the appropriate HCP will be contacted for clarification. If needed, 3 subsequent attempts will be made at intervals of approximately 2 weeks. If no further information is obtained, qualified registry staff or the principal investigator will make a logical determination on discrepant information based on the available data. All clarifications and/or changes will be documented and traceable.

20. ANNEX 4. LIST OF KNOWN TERATOGENS

This list will be updated over the course of the study as new teratogens are identified.

Drug class/generic name	Half-life	Relevant exposure window
Androgens		
Methyltestosterone	6 to 8 h	First, second, and third trimesters
Testosterone	Plasma half-life of testosterone ranges from 10 to 100 min. The cypionate and enanthate esters of testosterone have longer durations of action than testosterone. Cypionate half-life is about 8 d.	First, second, and third trimesters
Mesterolone	12 to 13 h	Not in TERIS. Assumed window: first, second, and third trimesters
Nandrolone	144 to 288 h	Unknown. Assumed window: first, second, and third trimesters
Oxandrolone	13.3 h	Unknown. Assumed window: first, second, and third trimesters
Prasterone	12 h	Unknown. Assumed window: first, second, and third trimesters
Fluoxymesterone	9.2 h	Unknown. Assumed window: first, second, and third trimesters
Angiotensin II receptor antagonists		
Azilsartan	11 h	First, second, and third trimester
Candesartan	9 h	First, second, and third trimesters
Eprosartan	20 h	First, second, and third trimesters
Irbesartan	11 to 15 h	First, second, and third trimesters
Losartan	2 h	First, second, and third trimesters
Olmesartan	13 h	First, second, and third trimesters
Tasosartan	Not available, but half-life of angiotensin II receptor antagonists ranges from 1 to 3 d	First, second, and third trimesters
Telmisartan	24 h	First, second, and third trimesters
Valsartan	6 h	First, second, and third trimesters
Angiotensin-converting enzyme inhibitors		
Benazepril	10 to 11 h	First, second, and third trimesters
Captopril	2 h	First, second, and third trimesters
Cilazapril	9 h	First, second, and third trimesters
Enalapril	11 h	First, second, and third trimesters
Fosinopril	11.5 to 14 h	First, second, and third trimesters
Lisinopril	12 h	First, second, and third trimesters

Drug class/generic name	Half-life	Relevant exposure window
Moexipril	12 h	First, second, and third trimesters
Perindopril	0.8 to 1 h	First, second, and third trimesters
Quinapril	3 h	First, second, and third trimesters
Ramipril	13 to 17 h	First, second, and third trimesters
Trandolapril	6 h	First, second, and third trimesters
Anti-arrhythmics		
Amiodarone	61 d	First, second, and third trimesters
Antibiotics		
Sulfamethoxazole/ Trimethoprim	8 to 10 h	3 months before conception and first trimester for MCMs and second trimester for preterm birth and low birth weight
Anticoagulants		
Acenocoumarol	8 to 11 h	First, second, and third trimesters
Dicumarol	1 to 2 d	At least 2 weeks before conception and first, second, and third trimesters
Phenprocoumon (Fenprocoumon)	4 to 6 d	First, second, and third trimesters
Warfarin	40 h	At least 2 weeks before conception and first, second, and third trimesters
Anti-epileptics		
Trimethadione/ Paramethadione	Paramethadione—12 to 24 h Trimethadione—11 to 16 h	First, second, and third trimesters
Valproic Acid, Valproate	9 to 16 h	Primarily first trimester, but MCMs have been associated with second and third trimester exposures
Carbamazepine	12 to 65 h	First, second, and third trimesters
Ethotoin	3 to 9 h	First, second, and third trimesters
Phenytoin, Fosphenytoin	Phenytoin: 7 to 42 h Fosphenytoin: 15 min	First, second, and third trimesters
Primidone	10 h	First, second, and third trimesters
Topiramate	21 h	First, second, and third trimesters
Ethosuximide	17 to 56 h	Unknown. Assumed window: first, second, and third trimesters
Oxcarbazepine	Oxcarbazepine: immediate-release formulations, about 2 h; extended-release tablet, 7 to 11 h Active metabolite, 10–monohydroxy: 9 to 11 h	Unknown. Assumed window: first, second, and third trimesters

Drug class/generic name	Half-life	Relevant exposure window
Sulthiame	24 h	Not in TERIS. Assumed window: first, second, and third trimesters
Vigabatrin	10.5 h	Unknown. Assumed window: first, second, and third trimesters
Phenobarbital	70 to 140 h	First, second, and third trimesters
Methylphenobarbital	34 h	Unknown. Assumed window: first, second, and third trimesters
Antifungals		
Fluconazole	30 h	2 weeks before conception and first trimester
Flucytosine	2.4 to 4.8 h	First trimester
Antineoplastics		
Aminopterin	12 to 24 h	First, second, and third trimesters
Asparaginase	5.7 d	3 months before conception and first, second, and third trimesters
Axitinib	2.5 to 6.1 h	1 week before conception and first, second, and third trimesters
Brentuximab vedotin	4 to 6 d	6 months before conception and first, second, and third trimesters
Methotrexate	55 h	6 months before conception and first, second, and third trimesters
Crizotinib	42 h	45 days before conception and first, second, and third trimesters
Cytarabine	1 to 3 h	6 months before conception and first, second, and third trimesters
Daunorubicin	The plasma half-life of daunorubicin averages 45 min in the initial phase and 18.5 h in the terminal phase. By 1 h after administration of daunorubicin, the predominant form of the drug in plasma is the metabolite daunorubicinol, which has as average terminal plasma half-life of 26.7 h	6 months before conception and first, second, and third trimesters
Exemestane	24 h	1 month before conception and first, second, and third trimesters
Mechlorethamine	15 min	First, second, and third trimesters
Mercaptopurine	10 h	6 months before conception and first, second, and third trimesters.
Vinblastine	24.8 h	First, second, and third trimesters
Cyclophosphamide	3 to 12 h	12 months before conception and first trimester
Altretamine	4.7 to 10.2 h	Unknown. Assumed window: first, second, and third trimesters

Drug class/generic name	Half-life	Relevant exposure window
Amsacrine	8 to 9 h	3 months before conception and first, second, and third trimesters
Bevacizumab	480 h	6 months before conception and first, second, and third trimesters
Bleomycin	2 h	Unknown. Assumed window: first, second, and third trimesters
Bortezomib	40 to 193 h	7 months before conception and first, second, and third trimesters
Busulfan	2.3 to 3.4 h	6 months before conception and first, second, and third trimesters
Capecitabine	0.75 h	6 months before conception and first, second, and third trimesters
Carboplatin	2.6 to 5.9 h	Not in TERIS. Assumed window: first, second, and third trimesters
Carmustine	IV, 15 to 75 min	3 months before conception and first, second, and third trimesters
Cetuximab	63 to 230 h	2 months before conception and first, second, and third trimesters
Chlorambucil	1.5 h	Not in TERIS. Assumed window: first, second, and third trimesters
Cisplatin	20 to 30 min	12 months before conception and first, second, and third trimesters
Cladribine	1 d	6 months before conception and first, second, and third trimesters
Clofarabine	5.2 h	6 months before conception and first, second, and third trimesters
Dacarbazine	5 h	Unknown. Assumed window: first, second, and third trimesters
Dactinomycin	36 h	6 months before conception and first, second, and third trimesters
Dasatinib	3 to 5 h	Unknown. Assumed window: first, second, and third trimesters
Docetaxel	11.1 h	6 months before conception and first, second, and third trimesters
Doxorubicin	20 to 48 h	6 months before conception and first, second, and third trimesters
Epirubicin	31.1 h ± 6 h to 35.3 h ± 9 h	6 months before conception and first, second, and third trimesters
Erlotinib	36.2 h	2 weeks before conception and first, second, and third trimesters
Estramustine	10 to 20 h	Not in TERIS. Assumed window: first, second, and third trimesters
Etoposide	4 to 11 h	6 months before conception and first, second, and third trimesters

Drug class/generic name	Half-life	Relevant exposure window
Fludarabine	20 h	6 months before conception and first, second, and third trimesters
Fluorouracil	8 to 20 min	3 months before conception and first, second, and third trimesters
Gemcitabine	1.7 to 19.4 h	6 months before conception and first, second, and third trimesters
Hydroxycarbamide	2 to 4.5 h	Unknown. Assumed window: first, second, and third trimesters
Idarubicin	20 to 22 h	6.5 months before conception and first, second, and third trimesters
Ifosfamide	15 h	Unknown. Assumed window: first, second, and third trimesters
Imatinib	18 h	2 weeks before conception and first, second, and third trimesters
Irinotecan	6 to 12 h	6 months before conception and first, second, and third trimesters
Lapatinib	24 h	1 week before conception and first, second, and third trimesters
Lomustine	16 to 48 h	2 weeks before conception and first, second, and third trimesters
Melphalan	10 to 75 min	Unknown. Assumed window: first, second, and third trimesters
Mitocycine	46 min	6 months before conception and first, second, and third trimesters
Mitoxantrone	23 to 215 h	Not in TERIS. Assumed window: first, second, and third trimesters
Nelarabine	Adults: prodrug: 30 min; ara-G: 3 h	Unknown. Assumed window: first, second, and third trimesters
Oxaliplatin	392 h	9 months before conception and first, second, and third trimesters
Paclitaxel	13 to 52 h	6 months before conception and first, second, and third trimesters
Pemetrexed	3.5 h	6 months before conception and first, second, and third trimesters
Pembrolizumab	22 d	4 months before conception and first, second, and third trimesters
Pentostatin	5.7 h	Not in TERIS. Assumed window: first, second, and third trimesters
Procarbazine	IV, approximately 10 min	Not in TERIS. Assumed window: first, second, and third trimesters
Raltitrexed	260 h	6 months before conception and first, second, and third trimesters
Sorafenib	25 to 48 h	6 months before conception and first, second, and third trimesters

Drug class/generic name	Half-life	Relevant exposure window
Streptozocine	Systemic: 35 min unchanged drug; 40 h metabolites	6 months before conception and first, second, and third trimesters
Sunitinib	40 to 60 h	1 month before conception and first, second, and third trimesters
Tegafur	6.7 to 11.3 h	6 months before conception and first, second, and third trimesters
Temozolomide	1.8 h	6 months before conception and first, second, and third trimesters
Teniposide	5 h	Not in TERIS. Assumed window: first, second, and third trimesters
Thioguanine	80 min	Not in TERIS. Assumed window: first, second, and third trimesters
Thiotepa	1.4 to 3.7 h	6 months before conception and first, second, and third trimesters
Topotecan	2 to 3 h	6 months before conception and first, second, and third trimesters
Vincristine	85 h	Unknown. Assumed window: first, second, and third trimesters
Vindesine	2.9 h	Not in TERIS. Assumed window: first, second, and third trimesters
Vinorelbine	27.7 to 43.6 h	6 months before conception and first, second, and third trimesters
Lenalidomide	3 h	4 weeks before conception and first, second, and third trimesters
Antithyroid		
Propylthiouracil	1 to 2 h	First and second trimesters
Methimazole	4.9 to 5.7 h	First, second, and third trimesters
Radioiodine	192 h	6-12 months before conception and first, second, and third trimesters
Antivirals		
Ribavirin	12 d	6 months before conception and first, second, and third trimesters
Endothelin receptor antagonist		
Ambrisentan	15 h	1 month before LMP and first, second, and third trimesters
Bosentan	5 h	1 month before LMP and first, second, and third trimesters
Macitentan	16 to 48 h	1 month before LMP and first, second, and third trimesters
Estrogens		
Diethylstilbestrol	Diethylstilbestrol reaches peak concentration within 20 to 40 min, having a primary half-life of 3 to	First, second, and third trimesters

Drug class/generic name	Half-life	Relevant exposure window
	6 h. It has a terminal half-life of 2 to 3 d due to entero-hepatic circulation	
Immunomodulatory agents		
Mycophenolate mofetil	16 h	First, second, and third trimesters
Thalidomide	5 to 7 h	1 month before conception and first, second, and third trimesters
Penicillamine	2 to 4 h	First, second, and third trimesters
Azathioprine	5 h	Primarily first trimester, but other outcomes have been associated with exposures “during pregnancy”
Leflunomide	432 to 456 h	2 years before conception and first, second, and third trimesters
Mycophenolic acid	8 to 16 h	Primarily first trimester, but other outcomes have been associated with exposures “during pregnancy”
Mood stabilizer		
Lithium	24 h	First, second, and third trimesters
Prostaglandin analogues		
Misoprostol	20 to 40 min	1 month before conception and first, second, and third trimesters
Retinoids		
Alitretinoin	9 h	1 month before conception and first, second, and third trimesters
Tretinoin	0.5 to 2 h	Unknown. Assumed window: first, second, and third trimesters
Vitamin A	TERIS only notes “long half-life”	Doses above 10,000 IU/day may be teratogenic: First, second, and third trimesters
Acitretin	acitretin: 33 to 96 h cis-acitretin: 28 to 157 h	3 years before conception and throughout pregnancy, especially first trimester
Etretinate	120 d to 3 y	3 years before conception and throughout pregnancy, especially first trimester
Isotretinoin	10 to 12 h	1 month before conception and first, second, and third trimesters
Tazarotene	18 h	First, second, and third trimesters
Retinol	2 to 9 h	12 months before conception and first trimester
Selective serotonin reuptake inhibitor		
Paroxetine	21 h	First, second, and third trimesters
Steroids		

Drug class/generic name	Half-life	Relevant exposure window
Danazol	9.7 to 23.7 h	First, second, and third trimesters
Tetracyclines		
Demeclocycline	10 to 17 h	Second and third trimesters
Oxytetracycline	6 to 11 h	Second and third trimesters
Tetracycline	6 to 11 h	Second and third trimesters; limited data for first trimester exposure
Chlortetracycline	5.6 h	Unknown. Assumed window: second and third trimesters
Doxycycline	18 to 22 h	Unknown. Assumed window: second and third trimesters
Methacycline	14 to 22 h	Unknown. Assumed window: second and third trimesters
Minocycline	11 to 24.31 h	Unknown. Assumed window: second and third trimesters
Tigecycline	27 to 43 h	Unknown. Assumed window: second and third trimesters
Other		
Methylene blue	24 h	Unknown. Assumed window: 1 month before LMP and first, second, and third trimesters
Riociguat	7 to 12 h	1 month before LMP and first, second, and third trimesters
Sparsentan	9.6 h	Unknown. Assumed window: 1 month before LMP and first, second, and third trimesters

ara-G = arabinosyl guanine; IV = intravenous; MCM = major congenital malformation; TERIS = Teratogen Information System

Sources: Eltonsy et al. 2016; TERIS 2021; DrugBank online available at <https://go.drugbank.com>; product labels, which are available at: <https://www.accessdata.fda.gov/scripts/cder/daf/> and <https://dailymed.nlm.nih.gov/dailymed/index.cfm> summary of product characteristics at <https://www.ema.europa.eu/en/medicines> and <https://products.mhra.gov.uk/>, product monographs at <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>.